

Systematic Review

An Update on the Etiopathogenesis of NAFLD including Organokines for Early Diagnosis and Improvement of Management and Preventing Early HCC Development: A Narrative Review

 **Kulvinder K. Kaur, MD^{1*}; Gautam N. Allahbadia, MD²; Mandeep Singh, MD²**

¹Centre for Human Reproduction 721, Jalandhar 144001, Punjab, India

²Swami Satyanand Hospital, Jalandhar 144001, Punjab, India

*Corresponding author

Kulvinder K. Kaur, MD

Scientific Director, Centre for Human Reproduction 721, Jalandhar 144001, Punjab, India; Tel. 91-181-4613422; Fax. 91-181-4613422;

E-mail: kulvinder.dr@gmail.com

Article information

Received: December 19th, 2022; **Revised:** April 26th, 2023; **Accepted:** May 18th, 2023; **Published:** May 25th, 2023

Cite this article

Kaur KK, Allahbadia GN, Singh M. An update on the etiopathogenesis of NAFLD including Organokines for early diagnosis and improvement of management and preventing early HCC development: A narrative review. *Liver Res Open J.* 2023; 4(1): 18-41. doi: [10.17140/LROJ-4-115](https://doi.org/10.17140/LROJ-4-115)

ABSTRACT

Background

Earlier, we reviewed different methods of treating non-alcoholic fatty acid liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), concentrated on organokines liberated by adipose tissue (AT) and liver (adipokines and hepatokines), adipokines in obesity with heart failure (HF), and myokines like irisin in exercise in obesity, and thought they might work as diagnostic and therapeutic targets in NAFLD and NASH with hepatocellular carcinoma (HCC). These are believed to be biological markers that can anticipate the robustness of NAFLD from NAFLD to HCC.

Methods

We conducted a narrative review utilizing search engines PubMed, Google Scholar; Web of Science; Embase; Cochrane Library utilizing the MeSH terms “NAFLD”; “NASH”; “Organokines”; “Adipokines”; “Hepatokines”; “Myokines”; “Osteokines”; “Stellakines”; “Fructose”; “Gut Microbiota”; “Insulin resistance (IR)”; “Crosstalk of organokines”; “Obesity”; “T2D” from last 10-years till date in 2023.

Results

We found a total of 750 articles, out of which we selected 95 for this review. No meta-analysis has been done.

Conclusion

As acknowledged earlier, NAFLD possesses the characteristics of simple steatosis, while NASH progresses to hepatic steatosis, lobular inflammation, and an escalated diameter of hepatocytes (ballooning of hepatocytes) with or without fibrosis in 20% of cases of NAFLD. Usually, it is correlated with metabolic diseases like obesity, type 2 diabetes mellitus (T2DM), and metabolic syndrome (MetS); hence, the liberation of organokines gets manipulated in a way that might aid in the etiopathogenesis or propagation of disease. We observed that insulin resistance (IR), oxidative stress (OS), mitochondrial impairment, fructose, and gut microbiota reflected factors taking part in the development and propagation of NASH. Alterations in various organokines (inclusive of adipokines, hepatokines, myokines, osteokines, and a newer one, stellakines) produced by hepatic stellate cells (HSCs) were further seen to directly or indirectly aid in the exacerbation and propagation of disease or cause dysfunctional homeostasis. Moreover, we discuss the role of stellakines in detail, and targeting silymarin might give us an efficacious drug for the early treatment of NAFLD or NASH.

Keywords

Non-alcoholic fatty acid liver disease (NAFLD); Organokines; Oxidative stress; Inflammation; Dyslipidemia.

INTRODUCTION

Non-alcoholic fatty acid liver disease (NAFLD), by definition, is macro-vesicular steatosis (fat accrual) is greater than 5% of the hepatocyte without any other etiology like alcohol or any prior liver disease. Non-alcoholic steatohepatitis (NASH) occurs as a complication of NAFLD. Besides steatosis, it possesses the properties of lobular inflammation along with the escalated diameter of hepatocytes (ballooning of hepatocytes) with or without fibrosis and implicates about 20% of subjects with NAFLD. This type of alteration has been noticeable on histological evaluation in addition to the presence of fibrosis, which displays the deterioration of the case. The propagation is correlated with cirrhosis, hepatocellular carcinoma (HCC), and liver transplantation, along with escalated mortality due to liver reasons.¹ NAFLD is believed to be the hepatic constituent of metabolic syndrome (MetS), besides being intricately associated with metabolic diseases like obesity, type 2 diabetes mellitus (T2DM), and atherosclerosis.^{2,3} Based on these characteristics, an International Expert Consensus Statement pointed out that utilization of a new definition should be made regarding metabolic impairment associated fatty liver disease (MAFLD).⁴ The diagnostic criteria advocated were the existence of hepatic steatosis, obesity, and T2DM, or metabolic impairment.⁵ Despite this, it would express the intricate association of fatty liver with excessive feeding, sedentary lifestyle, and medical situations (like hypertension, T2DM, or dyslipidemia), and obesity.⁶ Nevertheless, no consensus was reached regarding these criteria, which were believed to be irrelevant regarding clinical scenarios since certain non-obese non-diabetic patients with hepatic steatosis were not diagnosed in view of the absence of laboratory investigations for metabolic impairment.⁶

The insight regarding the pathophysiology of NASH was generated from the lucrative theory in the etiopathogenesis of NAFLD, namely the “2hit” posit.⁷ The first hit is insulin resistance (IR), secondary to escalated fatty acid (FA) flux; the second is inflammation, correlated with gut-obtained endotoxins, oxidative stress (OS), and mitochondrial impairment; however, it was not enough to detail the numerous molecular pathways along with metabolic events in NASH formation. Hence, a “multi-hit” model was posited more recently in view of it taking into account various damages taking place simultaneously in genetically prone subjects (Palatin-like PhosphoLipaseA2Domain-Containing 3 (PNPLA3), along with *TM6SF2* genes) like nutritional, intestinal microbiota IR, hormones liberated by adipose tissue (AT), genetic, and epigenetic factors (Figure 1).^{1,8-11}

The determination of NASH prevalence is tough in view of the need for a liver biopsy, which is the gold standard for diagnosis, though this is not performed routinely. Indirect pointers state that 3-6% of Americans manifest NASH, with greater prevalence in subjects with prior-generated metabolic diseases, with 20% propagating to cirrhosis.^{1,12}

Taking into account that NAFLD impacts as many as 1 billion individuals globally and that its prevalence is correlated with escalating obesity and MetS, it has been predicted that a set of both these disorders (NAFLD and NASH) would be impli-

cated as the major etiology of liver transplantation.^{8,12}

As far as the etiology is concerned, the primary factors correlated with NAFLD and NASH are: i) IR; ii) obesity; iii) T2DM; and iv) MetS. Other endocrine diseases like hypothyroidism and polycystic ovary syndrome (PCOS) can be correlated with them in view of their sharing the elemental pathophysiological modes of NAFLD, IR, obstructive sleep apnea syndrome, hypertension, dyslipidemia, alterations in the intestinal microbiota, genetic proneness, menopause, a lifestyle with decreased physical activity, and an escalated intake of fructose and saturated fatty acids along with carbohydrates.^{1,13}

In view of liver impairment, the liberation of hepatokines further alters. Furthermore, the correlated metabolic alterations result in changes in the liberation of other organokines that further modulate NASH in the etiopathogenesis and propagation of the disease.¹⁴ Earlier, we reviewed different methods of treating NAFLD and NASH and concentrated on organokines liberated by AT and the liver, which are key organs for controlling lipid metabolism, basically adipokines and hepatokines.¹⁵⁻³² Furthermore, we reviewed the role of adipokines in obesity with heart failure (HF) and those of myokines like irisin in exercise regarding obesity^{15,16} and thought they might work in the form of diagnostic and therapeutic targets in NAFLD and NASH obtained HCC. These are believed to be biological markers that can anticipate the robustness of NAFLD from NAFLD to HCC. In view of these, we decided to review more detailed parts of organokines in NASH propagation, inclusive of osteokines like bone morphogenetic protein (BMP), osteocalcin, and myokines in NASH and their crosstalk impacting the disease, besides overlap of certain organokines as both adipokines and myokines, or say adipokines and hepatokines, adipokines, and osteokines occur.

METHODS

We conducted a narrative review utilizing search engines PubMed, Google Scholar, Web of Science, Embase, and the Cochrane Library utilizing the MeSH terms “NAFLD”, “NASH”, “organokines”, “adipokines”, “hepatokines”, “myokines”, “osteokines”, “stellakines”, “fructose”, “gut microbiota”, “insulin resistance”, “crosstalk of organokines”, “obesity” and “type 2 diabetes (T2D)” from the last 10-years to date in 2023.


RESULTS

We found a total of 750 articles, out of which we selected 145 for this systematic review. No meta-analysis was performed.

PARTS OF INSULIN RESISTANCE, FRUCTOSE, GUT MICROBIOTA AND ORGANOKINES

Insulin Resistance, Inflammation besides Mitochondrial Impairment

IR possesses a key role in the pathophysiology of NAFLD and NASH. In general, insulin possesses a controlling function in hepatic metabolic events. Furthermore, it works on other peripheral



cells implicated in glucose uptake, its storage (glucogenesis), and protein production, in addition to fatty acid generation. Conversely, it possesses a blocking action over catabolic events like lipolysis, glycogenolysis, proteolysis, and gluconeogenesis. Hence, resistance to its actions produces numerous inimical sequelae regarding the metabolism.³³

In cases of increased intake of nutrients (comprised of carbohydrates and lipids, besides fast foods) in association with a lifestyle of decreased physical activity, enhanced energy ingestion gets stored in AT. AT absorbs and stores glucose and free fatty acids (FFA), acting as a compensating mode to neutralize the probable toxic actions of these circulating nutrients, inclusive of adipocyte hypertrophy and hyperplasia. As a consequence of escalated nutrition, IR enhances the flow of FFA towards the liver by enhancing lipolysis and lipogenesis along with hampering esterification of FFA, forming an imbalance amongst generation and input *vis-à-vis* oxidation and exporting of hepatocellular fat.^{8,34}

Therefore, this kind of imbalance is implicated in escalated intrahepatic FA accrual. This accrual possesses lipotoxicity in view of cells having the incapacity of secluding greater reactive lipid molecules, which results in their mitochondrial oxidation enzymatic system being overloaded with resultant mitochondrial injury, endoplasmic reticulum (ER) stress, and autophagy. Obesity correlated with NASH causes adipocyte hypertrophy and cell degeneration, along with demise.^{1,8,35}

Hepatocyte demise is correlated with the liberation of damage-associated molecular patterns (DAMP) to the adjacent cells, which, *via* the inflammasome, get transformed into pro-inflammatory cytokines (interleukin-1 (IL-1) along with IL-18). On liberation, IL-1 causes the attraction of neutrophils. In addition to activating neutrophils, hepatic stellate cells (HSCs), along with

IL-18 liberation, cause the attraction and activation of macrophages. The cause of these reactions is the stimulation of innate immunity by DAMPs *via* pattern recognition receptors (PRR), hence activating transcription factor nuclear factor κ B (NF κ B), which stimulates the pro-inflammatory effect in NASH. This is followed by stepwise pro-inflammatory cytokines along with chemokine liberation like tumor necrosis factor- α (TNF- α) and IL-6, which ends in the generation of reactive oxygen species (ROS). This whole scenario, in addition to liver sinusoidal endothelial cells (LSECs), possesses a direct effect on fibrosis along with the provision of a milieu of chronic regeneration that facilitates chromosomal abnormalities resulting in the formation of HCC.^{8,36}

The escalated quantities of ROS possess the capacity of initiating cell demise in hepatocytes by activation of a particular pathway, stimulating lipid peroxidation by compromising oxidation, leading to the decreased generation of reactive lipids. Such reactive molecules might further aggravate liver injury and facilitate the liberation of greater ROS outside hepatocytes, aiding in HSC activation along with extracellular matrix (ECM) getting deposited.^{35,37}

Generation of malondialdehyde (MDA) takes place in the event of peroxidation, which is further implicated for peri-sinusoidal along with periportal fibrosis by activation of NF κ B along with controlling the expression of pro-inflammatory cytokines like TNF- α along with IL-8. Such inflammatory biomarkers result in the activation of HSCs, which aids in fibrosis. Membrane phospholipid peroxidation changes their permeability and facilitates the ballooning of hepatocytes. This alteration might point to cytoskeletal injury with the incapacity of full programmed cell death (PCD). This alteration results in the accrual of hydrogen peroxide in hepatic peroxisomes, which, in combination with fer-

rous iron, generates free hydroxyl (OH) radicals that possess great reactivity with membrane phospholipids.^{35,38}

Lipotoxicity is correlated with the transit of mitochondrial membrane pores that cause a break in cellular respiration, the production of OS, and the extravasation of cytochrome c from the cytosolic matrix, which activates the apoptosome in apoptosis. The escalated free radicals impact the mitochondrial deoxyribonucleic acid (mit DNA), resulting in decreased oxidative phosphorylation as well as depletion of adenosine triphosphate (ATP) stores. The hampering of electron flow in the phosphorylation chain produces greater ROS, which further injures mitochondrial DNA, resulting in a vicious cycle. Thus, apoptosis gets given up on depletion of ATP, replaced by necrosis or necroptosis taking over—a mode implicating mitochondrial injury, OS, along with activation of c-Jun-N-terminal kinase (JNK).^{35,39}

Hence, variable pathological stimuli inclusive of hepatocyte demise and molecules liberated by AT along with intestinal pathogens might facilitate inflammation and fibrogenesis by activating Kupffer cells (KC) (alias resident liver macrophages). Obesity, along with KC, is a key part of the NASH pathophysiology. They facilitate the activation of M1-macrophages in contrast to the anti-inflammatory M2 macrophages. Activation of M1-macrophages generates different kinds of cytokines, which then enroll pro-inflammatory cells, thus exaggerating inflammation. These complicated sequences of processes finally end in the activation of HSCs, with subsequent escalated generation along with the deposition of ECM. Hence, depletion of adipocyte function


in addition to inflammation of AT (existence of IL-1, IL-6, and TNF) aids in the generation of adipose resistance to insulin.^{12,23,38}

Part of Fructose

Fructose possesses a noticeable role in NASH generation in view of its stimulation of hepatic fat accumulation and its correlation with MetS risk factors like hypertension, escalated serum triglycerides (TG), and IR. Noticeably, where fructose comes from sweetened fructose drinks apart from fruit ingestion, separate outcomes are obtained in view of the latter possessing lesser fructose quantities besides possessing antioxidants, which counteract the action of this monosaccharide.⁴⁰

Entry of fructose takes place in hepatocytes through glucose transporter 2 (GLUT2), and at the cellular level, it gets transformed into fructose-1 phosphate (F1P) by fructokinase. Subsequently, aldolase B acts on F1P, generating phosphotriose that can be transformed into glucose, lactate, and fatty acids. Following an acute fructose load, the lipogenic pathway that's usually less active gets overactive on an escalation of phosphotriose (Figure 2).^{38,41}

Additionally, decontrolling the hepatic entry as well as the metabolism of fructose ends in the escalated generation of acetyl CoA (glycolytic pathway) over the liver's oxidative ability, facilitating neolipogenesis *via* the activation of factors like sterol regulatory element binding protein 1c (SREBP1c) and carbohydrate responsive element binding glucose protein (ChREBP). As



a result of the activation of these factors, enhancement of fatty acid synthase (FASN) and acetyl CoA carboxylase (ACC) expression that controls lipid generation takes place. Saturation of the glycolytic pathway further facilitates the accrual of glycolytic intermediates that can get transformed into glycerol-3 phosphate that gets utilized in TG generation.^{41,42}

Hence, fructose is the most robust lipogenic carbohydrate in the generation of hepatic steatosis in view of its being a substrate in addition to an activator of neolipogenesis. Chronic consumption of fructose escalates the events by stimulating the generation of lipogenic enzymes. Neolipogenesis stimulation, along with lipid accumulation in the liver, can result in hepatic IR. Furthermore, fructose has been acknowledged to hamper adiponectin generation and liberation, aiding in escalated IR and facilitating hepatic steatosis. These processes can facilitate OS in view of mitochondrial impairment and ER stress, factors that stimulate inflammation and propagate from simple steatosis to NASH.^{41,43}

Fructose is immediately phosphorylated by fructokinase C without any negative feedback regulation. This event decreases the generation of ATP and results in its utilization in view of the fact that, whereas fructokinase phosphorylation is rapid, the cleavage response by aldolase B is comparatively slow.⁴¹ Hence, escalated fructose ingestion, which is more than advocated by the World Health Organization (WHO), which is 5% in contrast to the full advocated calories per day, can result in phosphate deficiency with the accrual of adenosine monophosphate (AMP) and sequentially escalated uric acid generation, with fructose reflecting the only common carbohydrate that generates uric acid in its metabolism.^{36,40} Activation of the enzyme AMP deaminase takes place subsequent to the reduction of intracellular phosphate, which transforms AMP into inosine monophosphate (IMP), leading to nucleotide renewal, which initiates the production of uric acid and aids in the generation of ROS.^{40,43}

Noticeably, it is of considerable importance that, despite the fact that glucose and fructose are isomers and hence possess the same formula (C₆H₁₂O₆), the initiation of metabolism of these 2 molecules varies. The major variation is the implication of phosphofructokinase (a controlling enzyme) in glucose metabolism but not in fructose metabolism. This variation to start with results in reduced intracellular phosphate and ATP quantities, along with uric acid production, which is adequate for the blockade of protein generation, stimulation of ROS, and mitochondrial impairment leading to the MetS phenotype. Subsequent to this stage, the metabolism of both carbohydrates is similar.^{40,44} Uric acid accrual can interfere with fatty acid oxidation (FAO) and decrease hepatic ATP quantities with transient blockade of protein generation (OS), along with mitochondrial impairment induction. Additionally, uric acid possesses direct pro-inflammatory actions by activating NF- κ B and inducing inflammatory cytokine liberation. Lastly, fructose leads to the rupture of tight intercellular junctions, aiding in the escalated intestinal permeability that helps endotoxin entry *via* the portal vein, leading to NASH becoming indelible.^{40,43,44}

Additionally, mitochondria possess enzymes possessing

sensitivity to OS (acotinase 2 along with enoyl CoA hydratase). In combination, fructose and uric acid decrease the effect of acotinase 2, an enzyme correlated with Krebs's Cycle that leads to the accrual of citrate. The escalated citrate is guided towards the cytoplasm, activating lipogenesis *via* stimulation of ATP citrate lyase. Moreover, it is noticeable that repeated sugar exposure led to glucose transport *via* GLUT5 as well as increased quantities of fructokinase in the liver, which escalated fructose absorption.^{40,45}

Escalated along with chronic ingestion of fructose in view of a greater glycemic index results in an escalated need for ER stress in view of a greater lipid metabolism. Hence, endoplasmic reticulum membrane proteins might be fractalized or lead to lipid accumulation, aiding in ER stress, inflammation, OS, and apoptosis. ER stress further indirectly stimulates TG accrual in the liver, leading to hepatic and adipose IR, as well as activating transcription factors correlated with inflammation and cell demise. Fructose facilitates the generation of saturated fatty acids that possess the capacity to activate toll-like receptor 4 (TLR4) in the liver. Such activation stimulates OS secondary to the generation of inflammatory cytokines. Moreover, ER stress and inflammation can result in the generation of DAMPs, which signal and aid in alterations of metabolism. Escalated fructose can alter the profile of organokines, with escalated formation of fetuin-A, fibroblast growth factor 21 (FGF21), leukocyte cell-derived chemotaxin (LECT), and angiotensin-like protein-8 (betatrophin/ANGPTL8) implicated in alterations in energy homeostasis in IR and that can aid in organ injury.^{8,41,46}

Role of Intestinal Microbiota

The liver obtains most of its intestinal blood flow *via* the portal system. Hence, it represents the initial line of defense regarding intestinally obtained toxins, along with exposure to numerous pathogen-associated molecular pattern receptors (PAMP): hence, the role of the gut microbiota (GM) in the pathophysiology of NASH is significant.⁴⁷ Escalated consumption of foods rich in sugar and fat is correlated with the robust elimination of bacterial spp. variations and a remarkable decrease in the full density of the microbiota. Secondary to that, advantageous bacteria might be eliminated, besides the pathological microbiota getting over-represented. Advantageous bacteria are inclusive of *Lactobacillus*, *Bifidobacterium*, *Ruminococcus*, *Roseburia*, *Faecalibacterium* and *Bacteroides* species (spp.) that possess anti-inflammatory actions besides being beneficial to the metabolic paradigm. Bacteria believed to damage the intestinal microbiota are *Clostridium*, *Enterobacter*, and *Enterococcus* spp. NASH patients have decreased quantities of *Bacteroides* in contrast to healthy subjects.⁴⁸ Dysbiosis facilitates the transport of bacteria in addition to bacterial products (endotoxins) (like lipopolysaccharide (LPS) that might be correlated with the generation of fibrosis by activation of HSCs) to the portal circulation, hence aiding in the activation of HSCs in the propagation of NAFLD to NASH. Diet-induced obesity (DIO) changes the expression along with the organization of tight junctions amongst intestinal cells, which is directly correlated with escalated intestinal permeability. Moreover, NASH patients possess an increased capacity of ethanol-generating bacteria, in particular *Escherichia*, pointing out that ethanol-generating

microbiota (Bacteroides, Bifidobacterium, and Clostridium) can work as a risk factor for NASH propagation. Hence, apart from pathologies that change the intestinal microbiota, its constituents are further impacted by diet.^{35,37,43,48}

Here, fructose is a significant constituent. It stimulates the alterations of the intestinal microbiota, decreasing the expression of cell junction proteins as well as impacting cell adhesion. These events aid in the endotoxin's entry *via* the portal vein, which stimulates the upregulation of lipogenic genes along with pro-inflammatory genes. The greater permeability aids in bacterial translocation from the intestine to the blood stream with the provision of signals to different organs, including the liver, a process that might stimulate the innate immune response along with escalating the pro-inflammatory reaction.^{35,43,49}

Scientific proof pointed out that alterations in lifestyle, sticking to a diet and exercising, in addition to decreased body weight, led to an improvement in NAFLD. Escalated dietary fiber ingestion, probiotics, prebiotics, and calorie limitations are advocated. Dietary fiber is the most indigestible part of major diets, impacting the modulation of digestion in the form of a substrate for microbial fermentation. Moreover, the breakdown of fibers, which work in the form of prebiotics, yields numerous short-chain fatty acids (SCFA) that confer protection to the structure and function of the intestinal barrier. A diet possessing high fibers escalates the quantities of Bifidobacterium in addition to reducing the Firmicutes : Bacteroides ratio in humans, apart from decreasing the eating quantities in view of escalated satiety aiding in caloric limitations, a factor leading to improvement of NASH. Certain studies illustrated that greater ingestion of insoluble fibers (7.5 g daily) possesses the capacity to improve three separate liver fibrosis scores (hepatic fibrosis index, fatty liver index, and liver fat index NAFLD).^{35,48,50}

Part of Diacylglycerol

Diacylglycerol (DAG) further possesses a key role in the pathophysiology of NASH, leading to hepatic IR and the propagation of liver steatosis. DAG is the second-last intermediate for TG generation and has been evaluated as the mediator of IR in hepatocytes by activation of protein kinase C epsilon kind (PKCε). PKCε phosphorylates the threonine residue on insulin receptors in hepatocytes, leading to dysfunctional insulin signaling in these cells and IR-obtained lipid depositing stimuli. Furthermore, in subjects with NAFLD or NASH, DAG expression in the liver is feasible in greater quantities, escalating TG generation remarkably. Escalated hepatic IR along with liver lipid generation is evaluated in the form of DAG-modulated liver fatty accrual along with steatohepatitis.⁵¹ Loomba et al⁵² assessed if antisense hampering of diacylglycerol-acetyl transferase (DGAT2) could efficaciously decrease liver fattening in subjects with diabetes and NAFLD and illustrated that hampering decreased liver fat quantities without resulting in hyperlipidemia.

ORGANOKINES

The endocrine workings of the liver, AT, and hepatic tissue are

significant regarding NASH generation. The tissues possess the capacity to generate a biomarker peptide that has been acknowledged to be an organokine (hepatokines, adipokines, and myokines, respectively), which crosstalk *via* autocrine, endocrine, and paracrine pathways. The working of the organokines in combination is associated with health or the generation of variable diseases. With the escalation of AT, an escalation of the liberation of pro-inflammatory organokines aiding in metabolic conditions like IR, T2D and MetS takes place.¹⁴

The intricate association between skeletal muscle and bone tissue is much greater than simple anatomy; these tissues are further physiologically communicated by the endocrine system, which finishes the biochemical crosstalk. On chronically escalated energy ingestion, an escalated adiposity along with lipid accumulation in the bone marrow and adjacent myocytes leads to the liberation of FFA that possess lipotoxicity for muscle and bone cells located there. A vicious cycle gets triggered by these events, with chronic low-grade systemic inflammation (LGI) ensuing and leading to dysfunctional metabolism. At the time of resistance exercises, the load application to skeletal muscle gets switched to bone, which, apart from muscle protein generation, further signals a greater energy need for promoting bone generation. Certain systemic mediators, including leptin, can start muscle hypertrophy along with bone generation, validating that these tissues get endocrine signals along with bone and muscle having a bidirectional pathway for biochemical signals. These signals are brought about by myokines, osteokines, and adipokines that have autocrine, paracrine, and endocrine actions, hence controlling muscle as well as bone metabolism.⁵³

In view of insulin being a generator of necessary hormones like insulin-like growth factor (IGF1), angiotensinogen, thrombopoietin, and hepcidin, the lipid imbalance secondary to hepatocyte injury and demise is further implicated in the decontrolling of the generation of organokines. There is a reduction in the expression of the insulin sensitizer and anti-inflammatory hormone adiponectin in NASH. Despite leptin being necessary for controlling the appetite in addition to escalating energy expenditure, its quantities are increased in obesity. Leptin facilitates fibrogenesis in stellate cells, which stimulates the generation of fibrogenic genes along with inflammation in T-cells.⁵⁴

Various myokines like irisin, IL-6, IGF1, brain-derived neurotrophic factor (BDNF), and myostatin influence actions on bone metabolism, both anabolic and catabolic. Conversely, osteokines like osteocalcin and sclerostin stimulate muscle anabolism and catabolism, respectively. Adipokines like adiponectin, leptin, and resistin, along with TNF, can further impact bone and muscle anabolism. Moreover, lipolytic myokines, like Irisin, along with IL-6, are associated with exercise-stimulated thermogenesis as well as darkening adipocytes.^{53,55}

Adipokines

Apart from its part in energy storage, aiding in thermoregulation, and influencing mechanical protection, the AT further works in the form of an endocrine organ, liberating bioactive peptides la-

beled as adipokines. These agents control lipid metabolism, apart from impacting insulin sensitivity, appetite, and fibrogenesis, along with fat accumulation in the liver. Their effect is directly associated with adipocyte hypertrophy, basically in obesity, and is correlated with mild inflammatory situations.⁵⁵ Apart from being involved in the etiopathogenesis of certain metabolic diseases, they mediate bone turnover, bone mineral density, and skeletal muscle catabolism in aging diseases like sarcopenia. The accumulation of visceral fat is correlated with increased quantities of adipokines.⁵³

Adiponectin: Adiponectin represents one of the adipocytokines that exists in large quantities, circulating in large amounts in the peripheral blood.^{24,31} Normally, adiponectin gets liberated by adipocytes and is present in a lot of isoforms (multimeric and monomeric forms possessing full length and globular sub-forms, along with certain oligomers) and facilitates insulin sensitivity in the liver, skeletal muscles, and AT that includes the ectopic components and confers protection to cardiac tissue. The greater the expression of adiponectin, the lesser the AT mass. These adipokines possess anti-inflammatory effects, escalate FAO, escalate glucose uptake in skeletal muscle, and hamper gluconeogenesis.⁵³ Adiponectin gets generated just by AT, stimulates the liberation of anti-inflammatory cytokines (IL-10), leads to blockade of NF κ B activation, and hampers the liberation of TNF- α as well as IL-6. Weight reduction stimulates its production.⁵⁶⁻⁵⁸ It is an anti-fibrotic, anti-inflammatory, and adipokine expressed by white in addition to brown adipocytes. Its decrease is directly associated with IR and glucose intolerance. A reduction in its quantities can be brought about by the escalation of pro-inflammatory cytokines. Apart from aiding in inflammation, these adipokines possess the properties of thermogenesis induction along with FAO in skeletal muscle as well as the liver.^{57,59} Furthermore, adiponectin possesses the capacity to induce HSC quiescence.⁶⁰ Hence, adiponectin can be believed to be an adipokine that confers protection. There is an inverse association of its quantities with RI, with a lesser association in obese subjects and patients with RI, like those with T2D, NASH, and hypertension.⁵⁶

Leptin: Leptin represents an adipocyte-formed hormone possessing a lot of functions, having its receptors broadly expressed in umpteen peripheral tissues along with the hypothalamus but none in AT.^{24,31} The basic function of leptin is to control body weight, food consumption behavior, and energy metabolism. In chronic low-grade inflammation along with obesity, leptin stimulates the generation of IL-6 and TNF- α along with decreased adiponectin. Escalated quantities of leptin lead to adiponectin resistance, resulting in restriction of muscle FAO and decreased lipolysis in AT, actions that get neutralized by exercise.⁵⁶ Leptin is associated with food ingestion and energy expenditure, and its influence on NAFLD might be associated with IR or failure of the anti-steatotic effect. Its liberation gets escalated by IL-1 besides TNF- α .^{56,57} Leptin increases glucose along with FFA absorption from the skeletal muscle, in addition to decreasing the quantities of intrahepatic lipids in view of FAO. The increased quantities of leptin aid in the effects of pro-inflammatory cytokines. Moreover, leptin stimulates the proliferation of HSCs along with the generation of profibrogenic and pro-inflammatory factors.

Greater leptin quantities have further been illustrated to be correlated with the propagation of NAFLD.⁵⁷ Lastly, it possesses the capacity of influencing a pro-inflammatory effect in view of disrupted relaxation of nitric oxide (NO) associated vessels through escalated OS as well as by escalated expression of endothelin, hence enhancement of angiotensin II, that in turn escalates the generation of leptin that further stimulates the liberation of pro-inflammatory biomarkers (like TNF- α , IL-6, besides monocyte chemoattractant protein 1 (MCP1) receptor escalating the expression of adhesion molecules (like vascular adhesion molecules (VCAM-1) intercellular cell adhesion molecule (ICAM-1), along with E-selectin).⁵⁶

Omentin: Omentin gets liberated from the AT of the omentum, which is a 34 KD protein implicated in controlling the adipocytes differentiation, maturation, energy metabolism, immune response, inflammation, and insulin sensitivity. Two homologous isoforms (Omentin 1 and Omentin 2) exist in the circulation, with Omentin 1 being the major isoform. Omentin 1 works with the utilization of AMPK, NF κ B/MAP-Kinase (extracellular signal kinase1/2 (ERK1/2), JNK, as well as p38) signaling systems *via* which it exerts anti-proliferative, anti-inflammatory, anti-oxidative, and angiopoietic actions. Omentin escalates insulin sensitivity along with sequential glucose absorption.³¹ Its major circulating type is omentin-1 (alias intelectin, a peptide comprised of 313 amino acids). Patients with glucose intolerance and diabetes that are newly diagnosed possess decreased quantities, aiding in arterial calcification. Its quantities are inversely associated with hyperglycemia, chemerin quantities, and inflammation, besides insulin resistance (namely, factors that facilitate the propagation of NASH).⁶¹ It can function in the form of an antiatherosclerotic agent and confer protection against liver diseases.⁵⁷

Resistin: Resistin represents a low molecular weight adipocytokine that aids in IR, inflammation, and OS.^{24,31} The basic biological actions of resistin get manifested *via* different molecular targets (like FFA transport protein 1, acetyl-coenzyme A (CoA)-carboxylase (ACC), and AMP-activated protein kinase (AMPK), CD36) and get influenced by the amelioration of glucose metabolism, hampering of FFA-oxidation, and uptake.³¹ Resistin gets expressed mainly by macrophages and gets liberated by them secondary to activation by pro-inflammatory cytokines. Resistin is associated with insulin resistance in obesity. It possesses a pro-inflammatory effect that stimulates the liberation of IL-12 and TNF- α .^{9,54,58} Furthermore, it stimulates angiogenesis along with skeletal muscle cell proliferation.⁹ It decreases the quantity of mitochondria and fat accumulation. Greater expression of resistin was observed in NASH in contrast to simple steatosis in control individuals.^{58,62} It gets generated by AT macrophages (ATM) along with monocytes, the induction of IR, angiogenesis, and skeletal muscle cell proliferation.⁶³

Vaspin: Vaspin gets generated by visceral AT (VAT), believed to be a member of the serine protease inhibitor family, capable of hampering Kallikrein 7, a protease possessing the capacity to breakdown insulin. In view of these, it can cause an improvement in glucose intolerance and insulin sensitivity and decrease the generation of pro-inflammatory cytokines, conferring protection to

vascular tissue from apoptosis. Greater serum quantities are associated with elderly obesity due to escalating insulin sensitivity and physical conditioning, along with lesser quantities of leptin.^{56,64}

Visfatin: Visfatin represents an inflammatory adipokine enzyme (alias nicotinamide phosphoribosyl transferase and pre-B-cell colony enhancing factor) that possesses growth factor action that is implicated in the generation pathway of nicotinamide adenine dinucleotide (NAD⁺), hence sirtuins (SIRT) function. It gets liberated actively by both adipocytes and macrophages; it is also observed in the circulation and in the ECM, where it controls the OS, immune response, apoptosis, and inflammation *via Sirt-1*-based and mitogen-activated protein kinases (MAPKs)-associated pathways.³¹ Visfatin is generated basically by adipocytes along with macrophages in AT and, to a lesser degree, by hepatocytes along with neutrophils. It is implicated in the conversion of pre-adipocytes to adipocytes along with generation, apart from the storage of triacylglycerols in AT.⁶⁵ It possesses immunomodulatory and vasodilatory characteristics in view of its ability to enhance the generation of NO. Conversely, it further displays pro-inflammatory effects, facilitating pancreatic β -cell impairment and leukocyte activation along with the generation of pro-inflammatory cytokines in AT, leading to the liberation of TNF- α , IL-6, vascular cell adhesion molecule 1 (VCAM-1), and IL-1 β (factors that result in dysfunctional insulin signaling).^{57,58,61} Moreover, visfatin stimulates endothelial proliferation along with the growth of smooth muscle cell factors. Its quantities are increased in obesity, MetS, T2D, or cardiovascular disease (CVD).

Myokines

Skeletal muscle is implicated in the liberation of myokines which can impact metabolic actions. This liberation is directly associated with continuous physical exercise. These organokines display how the muscle possesses the key liberating function, liberating peptides, and cytokines, in addition to growth factors. The kind of myokines liberated is associated with physical activity or lack along with the kind of muscle fiber as well as an exercise conducted.⁵⁷

Irisin: Irisin, a proteolytic hormone derivative (myokine) of the *fibronectin III domain-containing 5 (FNDC5)* gene, has been demonstrated in a mouse model to be induced by exercise (mediated by peroxisome proliferator-activated receptor- γ coactivator 1- α (PGC-1 α) and to then directly stimulate phenotypic changes in AT, which mediates changes in systemic metabolism. This irisin preferentially acts on the subcutaneous “beige” fat and causes it to brown by increasing the expression of uncoupling protein 1 (UCP-1) and other thermogenic genes.¹⁵ Irisin is associated with the control of energy homeostasis and metabolism, along with crosstalk amongst skeletal muscle as well as other tissues. The differentiation of white adipose tissue (WAT) in addition to brown adipose tissue (BAT) induction is one of its functions. This differentiation to BAT results in repression of adipogenesis, cholesterol formation, and the maximization of lipid oxidation, thus maximizing lipid homeostasis. In general, it gets liberated subsequent to physical exercise, and apparently it escalates insulin sensitivity in view of stimulation of the mobilization of glucose

transporters in insulin-based tissue, leading to enhancement of MetS as well as CVD. Apart from anabolic actions on bone, it escalates the generation of osteoblasts.^{53,60,65}

Polyzos et al⁶⁴ illustrated those greater quantities of this particular myokine existed in lean patients in contrast to obese patients as well as patients with NAFLD/NASH. Nevertheless, what was paradoxical regarding this study was that on portal inflammation evolution, an enhancement of irisin quantities might take place, which might be probably for restriction of inflammation as a compensating mode.⁶⁴


Mionectin: Mionectin gets liberated at the time of resistance exercises and escalates lipid uptake by AT along with the liver, decreasing quantities of plasma FFA. Reduction in physical activity decreases its quantities, escalating the quantities of FFA in the blood and resulting in FA accrual in other tissues, producing IR.⁶⁶ Moreover, it influences FFA absorption by cells, apart from coordinating metabolic events in different tissues.⁶⁶

Myostatin: Myostatin promotes muscle depletion by hampering tissue growth, stimulating tissue breakdown, and facilitating muscle atrophy. Decreased muscle mass escalates metabolic conditions. The skeletal muscle works as a major source of glucose-based uptake; loss of this mode results in compensation in other organs like the liver. Once exercise is continued regularly, its quantities decrease; hence, physical activity possesses a significant role in the form of a therapeutic target. Its quantities are greater in obese patients and are intricately associated with IR, facilitating the downregulation of GLUT4 expression. It escalates the pro-inflammatory milieu and hampers the liberation of antioxidants and anti-inflammatory agents. Its decrease is directly associated with decreased resistive index (RI), lesser fat accrual, producing muscle hypertrophy with control of oxidative metabolism of skeletal muscles, lipolysis in WAT along with darkening of adipocytes, reorganization of FFA, and utilization in lipogenesis for getting used for fuel (factors leading to the avoidance of the propagation of NASH) (Figure 3 for exercise, the liberation of myokines, and NASH).^{57,67}

Hepatokines

Hepatokines possess a necessary role in modulating metabolic events and pathological situations, basically in the form of liver-obtained pro-inflammatory factors.⁶⁵ Fetuin-A, fibroblast growth factor 21 (FGF21), selenoprotein P, sex hormone binding globulin (SHBG), angiopoietin-like protein-8 (betatrophin/ANGPTL8), and leukocyte cell-derived chemotaxin-2 (LECT2) are the ones that have been evaluated the most to date. The liver's capacity to influence glucose as well as metabolism by liberating these organokines into the blood, along with NAFLD, is apparently correlated with their changed formation. Moreover, hepatokines can be believed to be biomarkers of ectopic fat accumulation in the liver and markers of disease propagation. Certain hepatokines might be the target for avoidance along with therapy of diseases correlated with IR, including NAFLD.^{54,68}

Angiopoietin-Like Protein-8: Angiopoietin-Like Protein-8 (AN-



GPTL8/betatrophin) represents a circulating hepatokine also called TD26 and lipasin. It is significantly expressed in the liver and VAT. Overexpression of ANGPTL8 in BAT escalates lipoprotein lipase (LPL) action along with TG uptake. Serum ANGPTL8 has significantly escalated in patients with pre-diabetes and T2D.³¹ ANGPTL8 liberation by the liver takes place at the time of exercise. In view of it hampering pancreatic lipases, it hampers fat absorption. In the case of WAT, it stimulates lipolysis in addition to decreasing its growth. Its escalation is directly associated with IR as well as MetS.⁵⁷ Apart from that, it plays a part in the reorganization of FFA in skeletal muscles instead of storage in AT. There is a reduction in ANGPTL8 in obese subjects. Hence, the hampering of LPL gets influenced, leading to lipid accrual along with the probable evolution of NASH.^{67,69}

Leukocyte cell-derived chemotaxin2: Leukocyte cell-derived chemotaxin2 (LECT2) represents a neutrophil chemotactic organokine directly associated with metabolic stress in view of its leading to dysfunctional insulin signal transduction along with escalated inflammatory cytokines and adhesion molecules; escalated insulin sensitivity results from its depletion.⁵⁷

Additionally, it can pick up hepatic lipid steatosis as well as positively control itself *via* the activation of lipopolysaccharide (LPS) signaling in macrophages prior to weight accrual. Its expression is directly associated with escalated nutrition as well as, in turn, BMI along with liver inflammation in parallel with NASH generation.⁷⁰

Sex hormone binding globulin: Sex hormone binding globulin (SHBG) represents a protein that is basically liberated by the liver with the transportation of sex steroids to the target tissues. A reduction of SHBG takes place in T2D, obese subjects, and patients with hepatic liver steatosis, in contrast to subjects with no liver pathological conditions. The decreased expression of SHBG

in NAFLD might take place in view of inflammation, which, subsequent to TNF- α escalation in reaction to JNK and NF κ B activation, decreased its generation. Regarding metabolism, overexpression of SHBG confers protection against NAFLD by hampering hepatic lipogenesis *via* the downregulation of crucial lipogenic enzymes. Lifestyle manipulations, *via* obesity therapy as well as weight loss, result in increased circulating SHBG. Moreover, adiponectin escalated SHBG generation by activating the AMP-activated protein kinase (AMPK) and decreasing the action of enzymes implicated in liver lipogenesis. That is, with the reduction of quantities of hepatic SHBG in view of decreased hepatic generation due to escalated pro-inflammatory cytokines, hepatic lipogenesis gets facilitated. Hence, fat accumulation in the liver would decrease hepatic SHBG generation, which in turn would facilitate liver lipogenesis; hence, a vicious cycle gets triggered, which aggravates the generation of NAFLD.^{57,71}

On liver injury, SHBG generation gets interfered with like with other sex hormones. Hence, its quantities are decreased in steatosis, obesity, and T2D. In the case of PCOS, greater quantities of androgens are implicated in the reduction of their generation, which facilitates the initiation or propagation of liver diseases, including NASH and metabolic diseases.⁷²

Osteokines

The liberation of osteokines takes place by direct stimulation of osteocytes and osteoblasts by liberation of muscle matrix, producing a secondary reaction in the bone and other tissues with autocrine, endocrine, and paracrine effects. These osteokines possess systemic actions, with certain of them being osteocalcin (OCN) and BMP-7. OCN, sclerostin, and BMP are actively liberated by osteoblasts and can be liberated into the matrix at the time of bone resorption. Moreover, they possess considerably important actions on metabolism.^{56,67}

Bone morphogenetic protein: BMP represents a member of the TGF- β family, controlling variable events like organogenesis and paradigms of embryonic generation in addition to white and brown adipocyte generation. Expression of its sub-kinds in AT, along with its quantities in the blood, are associated with obesity and fat redistribution. BMP-7 is implicated in appetite control, and a reduction in food ingestion is proportional to the degree of its greater quantities. Moreover, the BMP-4 sub-kinds are liberated by adipocytes, leading to the stimulation of adipogenesis and guiding preadipocytes to a brown adipocyte phenotype. At the time of obesity, preadipocytes are resistant to these BMP actions, which might aid in obesity-associated diseases like NASH.⁵⁶

Moreover, BMP-7 stimulates the liberation of insulin by the pancreas. Hence, in view of its part in controlling food ingestion, energy expenditure, and AT formation, this class is necessary for the relief of obesity in addition to its associated co-morbidities (Figure 4 regarding the correlation of hepatokines along with adipokines in the propagation of fatty liver diseases).^{53,74}


Osteocalcin: OCN gets generated and liberated basically by osteoblasts, followed by activation by osteoclasts in bone resorption.⁷⁵ Its uncarboxylated and subcarboxylated (unOCN) kinds escalate insulin sensitivity and liberation by direct stimuli in the pancreas. Subsequent to exercise, unOCN quantities enhance, hence stimulating glucose uptake along with escalating insulin sensitivity, which is also associated with muscle hypertrophy and power. Uncarboxylated OCN stimulates glucose uptake and escalates insulin sensitivity and IL-6 sensitivity in skeletal muscles in rats; however, its effects are doubtful in humans.⁵³ OCN quantities are inversely associated with body mass index (BMI), IR, and inflammatory biomarkers, along with body fat mass. It facilitates the working and survival of pancreatic β -cells, enhancing insulin liberation, which by itself stimulates the liberation of OCN, hence gener-


ating a direct endocrine association between the bone and the pancreas. Moreover, it possesses advantageous actions in view of stimulating the generation of adiponectin along with IL-10. Conversely, it decreases TNF- α quantities in adipocytes and positively controls thermogenesis in AT and mitochondrial generation in skeletal muscles. Apart from that, it enhances glucose as well as FFA uptake by muscles.^{67,75}

Furthermore, OCN possesses an association with the nervous system. If it is lacking, the hippocampus is smaller and under-generated, which results in memory dysfunction, whereas its existence would be associated with a reduction in age-associated decreased cognition along with aid in reaction to acute stress, hampering the parasympathetic nervous system.⁷⁶⁻⁷⁸ Hence, OCN stimulates the ingestion of glucose along with FFA by facilitating the expression of fatty acid transporters and stimulating β -oxidation along with GLUT4 translocation to the plasma membrane. Hence, an anti-inflammatory milieu aids in decreasing visceral fat and decreasing NASH (Figure 5 illustrates the major organokines implicated in the formation of NASH).^{7,75,76}

Crosstalk Amongst Organokines

Apelin: Apelin, an adipocyte-derived hormone, was reported to promote brown adipocyte differentiation by apelin-AP1 signaling, both by increasing brown adipogenic and thermogenic transcriptional factors *via* the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and AMPK signaling pathways. They further reported that apelin relieves the TNF- α inhibition on brown adipogenesis and increases brown adipocyte activity, as shown by increased PGC-1 α and UCP-1 expression, mitochondrial biogenesis, and oxygen consumption.¹⁵ Apelin is formed by fat tissue and muscle, and in obesity, its reduction takes place. Moreover, its expression takes place in the central nervous system (CNS), hypothalamus,





heart, and stomach. It possesses a significant anti-inflammatory component, aiding in the regulation of heart muscle and, in turn, blood pressure (BP), besides cell cycle control and demise. This organokine further stimulates muscle regeneration, avoiding muscle depletion.^{58,79}

Furthermore, it controls glucose metabolism, lipolysis, and cardiovascular homeostasis, decreasing lipolysis along with vasodilation induction, which facilitates the decrease in BP. Conversely, greater circulating quantities point to apelin resistance alone and are seen in obesity besides IR.⁵⁶

Chemerin: Chemerin is believed to be an adipokine along with a hepatokine. Its expression takes place basically in WAT and gets liberated for controlling glucose uptake, lipolysis, and adipocyte differentiation. Its activation takes place by inflammatory and co-

agulation proteases.^{58,80} Apart from that, it is believed to be a chemoattractant for dendritic cells and macrophages. Additionally, it controls bone metabolism *via* testosterone (T) generation along with a balance between osteoblasts and osteoclasts.⁸⁰

Chemerin escalates glucose tolerance and hampers insulin signaling, along with possessing a part in bone breakdown besides its generation and stimulating inflammation.^{57,80} In view of the association between obesity and inflammation, it is escalated in NASH. Its quantities are directly correlated with components of MetS like escalated BMI, hypertension, escalated triglycerides (TG), and C-reactive protein (CRP) quantities. Chemerin quantities are elevated in obese as well as T2D subjects, with it possessing an inverse association with high-density lipoprotein-cholesterol (HDL-C) along with omentin quantities.^{61,81,82}

Fetuin A: Fetuin-A is one of the liberated glycoproteins believed to be the first hepatokine demonstrated to be correlated with metabolic diseases. Fetuin-A is positively correlated with hepatic steatosis and IR.¹ Its amounts are increased in patients with NAFLD, NASH, and T2DM. In the form of a significant source of NAFLD generation, FFA escalates pro-inflammatory fetuin-A expression. FFA-stimulated Fetuin A works as an endogenous ligand of TLR4 and accelerates lipid-modulated IR.³¹ Fetuin-A reflects an adipokine along with a hepatokine, and its escalated quantities are correlated with obesity, IR, T2D, and NAFLD, along with hampering ectopic calcium getting deposited.^{8,24} Fetuin-A facilitates the liberation of pro-inflammatory biomarkers in monocytes and adipocytes, along with downregulating the expression of adiponectin, an insulin-sensitizing hormone.^{54,56,65,68}

It naturally hampers insulin receptors in the liver and skeletal muscles, facilitating pro-adipogenic actions in view of its greater quantities that disturb the insulin signaling steps along with GLUT4 translocation.^{56,57} Hepatocytes liberate Fetuin-A in the blood, which binds to insulin receptors in tissues, hampering their signaling, in view of which IR results.⁶⁸ Moreover, Fetuin-A stimulates the liberation of inflammatory cytokines in monocytes, besides AT. Reduction in Fetuin-A results in advantageous actions in view of decreased accessible FFA, reducing visceral AT mass.⁵⁷

Fibroblast growth factor: FGF19 as well as FGF21 belong to the FGF family, which needs the Klotho proteins as cofactors. They stimulate FGFR4 along with Klotho, which has an abundance of expression in hepatocytes. FGF19 and FGF21 have the role of controlling glucose, lipid, and bile acid metabolism.³¹ FGF21 liberation takes place in AT, and the liver is a controller of glucose in addition to lipid metabolism. Its escalated quantities in NAFLD are associated with quantities of hepatic triglycerides; hence, FGF21 is believed to be an upcoming biomarker of NAFLD. It might be a probable therapeutic agent for tackling IR in view of its resulting improvement of insulin sensitivity, body weight, lipid profile, and hepatic IR, along with its potential role in inflammatory manipulation.¹ Furthermore, it stimulates the darkening of WAT.⁵⁸ In view of it stimulating the expression of thermogenic genes as well as adiponectin and FAO in the liver, along with insulin sensitivity. FGF21 escalates FAO in the liver, decreasing glucose generation, thus sequentially postponing steatohepatitis generation. It further escalates glucose retention in adipocytes in view of escalated GLUT1 expression, hence an improvement in insulin sensitivity. On FGF21 liberation into muscle, in reaction to insulin and escalated glucose uptake, it might stimulate bone resorption.^{53,54,57,65,68,80}

Follistatin: Follistatin reflects an adipokine as well as a myokine; it is liberated at the time of exercise, leading to the induction of thermogenic genes along with neutralizing myostatin.⁶⁶

Follistatin is basically liberated by the liver, and its quantities are escalated with an escalated glucagon: insulin ratio, like in fasting besides exercise. Patients presenting with IR secondary to obesity possess greater quantities of Follistatin. In view of its capacity to neutralize myostatin, it can escalate skeletal muscle

hypertrophy apart from inducing thermogenic genes in murine adipocytes. Its continuously escalated quantities are associated with IR, escalated hepatic glucose generation, and glucose intolerance. Conversely, temporary enhancement subsequent to physical activity is advantageous in view of it facilitating glucose as well as FFA uptake by skeletal muscle cells along with lipolysis in WAT.⁶⁷

IL-6: IL-6, a pro-inflammatory and prooncogenic cytokine, is believed to be an adipokine, a hepatokine, and a myokine. It is an anticipatory biomarker for IR as well as CVD. It represses adiponectin quantities along with those of TNF- α and stimulates leptin generation.^{9,66} The generation of IL-6 takes place in macrophages, which are stimulated by NF κ B activation. Hampering of insulin receptor substrate-1 (IRS-1), in addition to GLUT-4, in adipocytes.⁶⁶ Whereas IL-6 obtained from AT stimulates inflammation and glucose intolerance along with bone resorption, IL-6 obtained from myocytes possesses an anti-inflammatory effect in view of the fact that it liberates IL-10, generating an anti-inflammatory milieu, escalating glucose uptake, lipolysis in WAT, darkening of adipocytes, and metabolism improvement.^{53,57,67,80}

Lipocalin 2: Lipocalin 2 (LCN-2) (neutrophil gelatinase-associated lipocalin) gets liberated by different cell types belonging to the lipocalin protein superfamily. A broad expression occurs in AT, resulting in inflammation in addition to fibrosis. There is proof with regards to overexpression of LCN-2 in WAT getting regulated by upregulation of IL-1 β .³¹ LCN-2, initially believed to be an adipokine, was later observed to be an osteokine too. Its expression takes place in osteoblasts along with adipocytes and aids in a feeling of satiety and energy expenditure. Obese subjects might possess resistance to LCN-2, which escalates with aging and results in a reduction in energy expenditure.^{53,57} LCN-2 quantities were observed to escalate in animal models of diet-induced NASH liver injury and inflammation. This alteration was correlated with enhanced intrahepatic neutrophils along with the generation of pro-inflammatory cytokines that aided in the sustenance of inflammatory events.⁸² Hence, LCN-2 works as an inflammatory biomarker that is correlated with infections, ischemia, and renal inflammation, along with conditions like T2D and MetS.⁸³

Osteonectin: Osteonectin has been seen to be an adipokine and a myokine (alias secreted protein acidic and rich in cysteine (SPARC)). The expression of pro-inflammatory cytokines implicated in IR and adipogenesis stimulates insulin liberation along with erythropoiesis, which possesses a significant role in the avoidance of mitotic clonal expansion of preadipocytes, hampering the start of adipogenesis. In view of the hampering of adipocyte generation, it limits lipid storage, escalating circulating quantities and resulting in hyperlipidemia, followed by fat accumulation in the liver and skeletal muscle.⁵⁷

Mazzolini et al⁸⁴ found lesser quantities of SPARC to confer protection against NASH apart from decreased liver injury in robustly obese subjects. Consequently, its lack has been associated with changes in hepatic lipid metabolism and the chances of the generation of HCC, which is intricately associated with NAFLD.⁸⁵ The decreased quantities of FGF21 in adult patients with robust liver steatosis are in view of damage or demise sec-

ondary to lipotoxicity as well as hepatic inflammation. This decrease might further be correlated with disease propagation in NASH. The escalated FGF21 generation might be a probable factor that confers protection against carbohydrate as well as lipid metabolism conditions in view of SPARC directly controlling lipid metabolism and hepatic accrual in an insulin-independent way. Furthermore, it disrupts different paradigms of the “multi-hit” model of NAFLD like mitochondrial impairment, OS, chronic low-grade inflammation, and ER stress.⁸⁶

Selenoprotein P: Selenoprotein P (SeP) gets generated by the liver along with AT, aiding in the generation of IR as well as T2D.^{7,75} It functions in the form of intra-cellular antioxidants in phagocytes, reducing inflammatory reactions *via* the differentiation of macrophages from M1 to M2, decreasing oxidative injury, and hence avoiding injury to hepatic endothelial cells.

Nevertheless, its role has been contradictory regarding their quantities at the time of the inflammatory reaction, inclusive of metabolic diseases as well as the existence of NAFLD and NASH.^{56,57,64,67}

TNF- α : TNF- α is a cytokine that aids in steatosis, OS, and is an inflammatory mediator cytokine liberated by multiple inflammatory tissues apart from being an inducer of hepatocyte demise. Escalated quantities of TNF- α are correlated with obesity and IR *via* upregulation of suppressor of cytokines signaling 3 (SOCS3).⁷⁶ Hepatocytes contain TNF superfamily death receptors that get activated at the time of propagation from NAFLD to NASH. On

binding with TNF receptor-1 (TNFR1), induction of activation of caspase-3 and caspase-8 takes place, resulting in apoptosis of liver cells, a significant part in the breakdown of injured cellular constituents. At times of stress like inflammatory liver disease, apoptosis takes place for cell conservation; however, escalated apoptotic events might result in irreversible cell atrophy and its collapse, further aiding in the propagation of NASH.⁷⁷ TNF- α escalates lipolysis, hence escalating FFA quantities and facilitating the generation of IR. Moreover, by stimulating and activating vascular adhesion molecules, it promotes atherogenesis. The other mode implicated in TNF- α induction of IR in peripheral tissues is the activation of NF-B and stimulating cytokines along with adhesion molecules. Moreover, it works as a chemoattractant for monocytes and neutrophils. It escalates the cytotoxicity of monocytes and macrophages, acting simultaneously as a cytotoxicity mediator. The maximum of its functions get mediated by its capacity for the formation of other cytokines functionally correlated with TNF- α , ECM proteins, monocyte modulation, and fibroblast chemotaxis, apart from the expression of vascular adhesion molecules. Hence, in view of its multiple pro-inflammatory actions, it aids in NASH evolution.⁶¹

Transforming growth factor-beta: Transforming growth factor-beta (TGF- β) represents a pleiotropic cytokine implicated in proliferation, survival, differentiation, angiogenesis, and wound repair reactions. Certain studies pointed out that hepatocytes with escalated lipids escalate the generation of ROS modulated by TGF- β leading to the hepatocytes demise. Hence TGF- β signaling in hepatocytes aids in the hepatocytes’ lipid accumulation,




along with the generation of ROS, which facilitates the generation of NASH. In the liver, TGF- β signaling takes part in fibrogenic reactions *via* the activation of HSCs. Hence, TGF- β signaling in HSCs plays a significant role in the propagation of fibrosis in the case of advanced NAFLD (Figure 6 sums up the roles of different hepatokines implicated in the pathogenesis of NASH).⁷⁸

Stellakines

The activation of HSCs has a significant association with the propagation of chronic liver diseases, including liver cirrhosis and liver cancer. Activated HSCs liberate multiple pro-inflammatory factors and generate ECM constituents like α -SMA and type I and type III collagen fibers, which guide liver inflammation and manipulate hepatocyte demise, hence facilitating the generation of

liver disease.⁸⁷ Xiong et al⁸⁸ observed that activated HSCs in the NASH mouse model, apart from forming ECM constituents, liberated abundant signal protein molecules labeled as “stellakines”, like i) amyloid precursor protein (APP), ii) CC chemokines (like CCL2, CCL11), iii) macrophage-colony stimulating factor (M-CSF, alias CSF1), iv) connective tissue growth factor (CTGF, also called CCN2), and CXC chemokines (such as CXCL1, CXCL10) (Figure-7).

CSF1 along with periostin: CSF1 reflects a myeloid cytokine liberated at the time of infection and inflammation, which has further been illustrated to control the differentiation, proliferation, survival, and activation of monocytes and macrophages.⁸⁹ Mohallem et al⁹⁰ illustrated that colony stimulating factor receptor 1 (CSF-1R/CSF1) is considerably upregulated in cells treated



with TNF α -, pointing out that upregulation of CSF1 might activate pro-inflammatory reactions and leukocyte invasion of AT *via* non-classical activation of NF- κ B signaling modulated by the TNF receptor. The non-classical NF- κ B, the p52-RelB dimer, is believed to react to selective receptor signals that mediate adaptive immune functions. NF- κ B-inducing kinase (NIK) is a central constituent in the non-classical NF- κ B signaling pathway.⁹¹ Studies have further illustrated that the CSF1R facilitates the induction of non-classical NF- κ B signaling at the time of macrophage differentiation,⁹² which might possess the probability of hepatic healing in the case of fibrotic livers since macrophage accrual and phagocytic activity aid significantly in this event.⁹³ Periostin (POSTN) (another stellakine) is basically obtained from activated HSCs, and its main function is controlling cell adhesion, proliferation, migration, and apoptosis.⁹⁴ POSTN expression can be induced by NF- κ B and other pro-inflammatory transcription factors *in vitro*.^{80,95} Nevertheless, POSTN cooperates with TNF- α or IL-1 α to activate NF- κ B in fibroblasts and then induces the expression of CCL2/MCP1, CCL4/MCP1, CCL7/MCP3, CXCL1/KC, CXCL2/MIP-1 α , and IL-1 β .⁹⁶ These results show that crosstalk between POSTN and NF- κ B activation might be a crucial factor in controlling the inflammatory pathogenic association of NAFLD.

NTN1, GAS6 along with WNT4y: Netrin-1 (NTN1) is a member of the family of laminin-associated liberated proteins. NTN1 controls the activation of NF- κ B *via* the uncoordinated-phenotype-5A (alias UNC5A, an NTN1 receptor), and apart from the activation of UNC5A significantly, it activates the phosphorylation of NF- κ B/p65 at Ser536 however, UNC5A upregulates the expression of c-MYC (the NF- κ B downstream target) by activating NF- κ B to facilitate cell proliferation.⁹⁷ The *RAC1* gene is implicated in cellular growth and cell-cycle control. KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) is a long *non-coding ribonucleic acid* (RNA) gene. Interference or hampering of NTN1-NF- κ B further hampers cellular myelocytomatosis oncogene (c-MYC), resulting in downregulation of the expression of RAC1 and hampering of the hedgehog pathway through downregulation of KCNQ1OT1, finally hampering HSC proliferation and epithelial-mesenchymal transition (EMT) in liver fibrosis.⁹⁸

Growth arrest-specific 6 (GAS6) is believed to be implicated in the stimulation of cell proliferation. GAS6 hampers NF- κ B phosphorylation, chemotaxis, and adhesion affinity amongst monocytes and endothelial cells.⁹⁹ GAS6 avoids activation of TNF receptor-associated factor 6 (TRAF6) and NF- κ B by upregulating the suppressor of cytokine signaling 3 (SOCS3) in cellular models.¹⁰⁰ AS6-AS2 is an identified cancer-related lncRNA. TLR ligands reduce GAS6 by downregulating GAS6-AS2 expression *via* NF- κ B activation, pointing to a bidirectional feedback system between GAS6 and inflammation.⁸⁴ *WNT4* hampers NF- κ B by non-classical WNT signaling.¹⁰¹ WNT4 further activates β -catenin/NF- κ B by the working together of frizzled 4 and low-density lipoprotein receptor-related protein 6 (LRP6) signaling.¹⁰² Recombinant WNT4 proteins robustly hamper the apical step of TGF- β -activated kinase 1 phosphorylation, along with the following steps of receptor activator of nuclear factor kappa beta (NF κ B ligand) (RANKL) (RANKL induces each criti-

cal step in NF- κ B activation)-induced p65 phosphorylation and I κ B α phosphorylation and breakdown.^{101,103} Moreover, WNT4 further hampers NF- κ B-based transcription.¹⁰¹ These facts further illustrate that various genes crosstalk with NF- κ B to control the generation and propagation of NAFLD.

CXCL1, CXCR4/7 along with CXCL16: CXC chemokines are a chemokine subfamily with a CXC motif at the N-terminus, also called α -chemokines. Seventeen (17) CXC chemokines have been displayed (like CXCL1, CXCL10, CXCL12, CXCL14, and CXCL16). CXC chemokines impact tumorigenesis on cell enrollment, collection, migration, invasion, angiogenesis, angiostasis, and lymphangiogenesis.¹⁰⁴ CXCL1 has an extra ELR motif, and VEGF activity induces escalated expression of CXCL1 in endothelial cells, which induces angiogenesis *via* CXCR2 (the receptor of CXCL1).^{105,106} Activation of hypoxia-inducible factor-1 (HIF-1) and NF- κ B escalates CXCR2 expression in cancer cells at the time of chronic hypoxia.¹⁰⁷ In human umbilical vein endothelial cells (HUVECs), NF- κ B/p65 escalates the expression of long intergenic non-protein-coding RNA 1693 (LINC01693, which works as a miRNA-302d sponge) to escalate CXCL12 expression.¹⁰⁸ miRNA-302d reduces the expression of CXCL12, which illustrates that hypoxia enhances the expression of CXCL12 *via* NF- κ B.¹⁰⁴ Mallory-Denk bodies formed in human alcoholic hepatitis and NASH can mediate TLR3/4 signaling through the NF- κ B-CXCR4/7 pathway.¹⁰⁹ LPS and NF- κ B activation increase the expression of CXCL16 in HUVEC.¹¹⁰ Silencing of CXCL16 expression decreases tumor cell migration and proliferation *via* decreasing NF- κ B activation.¹¹¹

CCL11, CCL2, CXCL10 along with CTGF: CC chemokines are a subfamily of 27 chemokines that are implicated in intercellular connection and can further control the microenvironment in certain tumors.¹¹² Activation of ERK MAPK by CCL11 mediates apoptosis resistance in cancer cells.¹¹³ CCL11-CCR3 crosstalk activates the phosphatidylinositol 3-OH kinase/serine-threonine kinase (PI3K/Akt) signaling pathway in endothelial cells to induce angiogenesis.¹¹⁴ Moreover, activation of the CCR3 receptor by CCL11 escalates the expression of vascular endothelial growth factor (VEGF) in HCC, thus indirectly facilitating angiogenesis.¹¹⁵ It has been reported that macrophages with NF- κ B-mediated mixed canonical and signal transducer and activator of transcription (STAT)-6-mediated alternating activation phenotypes can generate CCL11.¹¹⁶ This incites the thought that NF- κ B regulation and activation of CCL11 can facilitate cancer angiogenesis and affect the prognosis of HCC. p50 can hamper liver inflammation and immune response by controlling CCL2 and CXCL10 liberation by HSCs, attenuating liver injury.¹¹⁷ p65 inhibits the activation of HSCs and reduces the liberation of stellakines in the inflammatory response.¹¹⁸ Tumor cell-derived connective tissue growth factors (CTGF) transmit growth-promoting signals to HCC cells by activating nearby HSCs, so CTGF has also been identified as a cornerstone in the HCC microenvironment, but anti-CTGF antibodies are prone to hampering this crosstalk.¹¹⁹ CTGF facilitates the nuclear accumulation of p50 and p65 to protect the survival of the primary HSCs. Chaqour et al¹¹⁸ illustrated that NF- κ B binds to the binding region in the promoter area of CTGF. Intranuclear translocation of NF- κ B *via* the Smad-

independent pathway can control CTGF expression, while TGF- β -induced CTGF expression is hampered by Bay 11-7082 (NF- κ B inhibitor).¹¹⁹

NAFLD AS WELL AS NASH-OBTAINED HCC

Pathogenesis of NAFLD and NASH-associated HCC

HCC is the third-commonest etiology of cancer-associated mortality. NAFLD as well as NASH-associated HCC represent the most rapidly escalated indication for liver transplantation. Cirrhosis exists in about 60% of cases of NAFLD as well as NASH-associated HCC.¹²⁰ This points out that HCC can be stimulated by NAFLD and NASH without cirrhosis. Hence, the belief is that inflammatory parameters will also play a key role in NAFLD or NASH-obtained HCC.

Gut-obtained Endotoxin

Already detailed how gut-obtained endotoxins work in the form of alternative inflammatory parameters and play a significant role in the generation of NAFLD and NASH. The amounts of LPS, alias endotoxins, are further escalated in the portal and peripheral venous veins of patients with HCC.¹²¹ They facilitate significantly the invasion potential besides inducing EMT, despite them hampering tumor growth as well.¹²² LPS stimulates JNK in addition to MAPK through TLR4 in HCC cells, while hampering JNK in addition to MAPK causes a significant reduction in EMT.¹²² Hence, LPS-TLR4 signaling might be one of the lucrative pathways for controlling the propagation from NAFLD-NASH to HCC.¹²³

Adipokines

Adipokines represent inflammatory parameters associated with HCC generation. Expression of adiponectin in human HCC has an inverse association with tumor size.¹²⁴ It escalates phosphorylation of JNK and activation of caspase-3, resulting in apoptosis in HCC.¹²⁴ The hampering of JNK phosphorylation avoids the anti-apoptotic actions of adiponectin.¹²⁴ Adiponectin has chemoshielding actions besides hepatoshielding actions through sulfatase 2 (SULF2) in HCC.¹²⁵ Adiponectin deletion facilitates fibrosis and HCC propagation in a choline-deficient NASH mouse model.¹²⁶ Conversely, high amounts of circulating adiponectin make it feasible to anticipate the subsequent generation of HCC along with poor HCC survival.¹²⁷ Moreover, adiponectin hampers the oncogenic action of leptin on cell proliferation, migration, and invasion of HCC.³¹

Leptin expression is increased in hepatoma tissues and cell lines.¹²⁸ Regulatory T-cells (TRegs), effector CD4+ T-cells, and CD8+ T-cells result in stimulation of the expression of the leptin receptor (LEPR) in the liver following the generation of HCC.¹²⁹ Macrophages and dendritic cells upregulate LEPR expression on T-cells. Leptin hampers activation of TRegs as well as function.¹²⁷ Escalated leptin expression in HCC is correlated with the expression of human telomerase reverse transcriptase (hTERT).¹²⁸ Leptin might play a key role in obesity-associated tumorigenesis. Adipokines that include adiponectin along with leptin are critical

actors in obesity-associated conditions and might be implicated in the etiopathogenesis of NAFLD and HCC.

UNEXPLORED PATHS

Variable and exciting queries might be there in view of these organokines influencing each other mutually and connecting *via* different endocrine, autocrine, and paracrine pathways. It has been acknowledged that variable environmental factors, including GM and genetic factors, are associated with the expression of organokines; however, which lifestyle alterations might modulate the expression of these mediators?

Which patients with NASH with a certain extent of therapeutic intervention (diet, physical activity, pharmacologic therapy) vary quantitatively as well as qualitatively in generating these organokines (hepatokines) in contrast to patients with decreased physical activity besides those without undergoing treatment?

Genetic Factors

We have already reviewed how recently the work of researchers aided in illustrating the mode of the risk of cardiovascular disease in sub-kinds of NAFLD (metabolic along with genetic). It has been established that carriers of numerous single nucleotide polymorphisms (SNPs) areas along with mitochondrial mutations possess greater proneness to NAFLD.¹¹ Nevertheless, conferring protection against coronary artery disease (CAD) was illustrated for different SNPs of this type,¹³⁰ which pointed out that each mutation region might implicate a distinctive mode of NAFLD proneness or CVD avoidance.¹³¹ Actually, recent meta-analysis research in the context of NAFLD proneness genes does not result in CAD intrinsically.¹³² Of the carriers of NAFLD SNPs, a robust association visualized total cholesterol (TC), along with low-density lipoprotein-cholesterol (LDL-C), with CAD, but not plasma TG, along with HDL-C. Enhancement of outflow of FAs as well as “*de novo*” lipogenesis starts the accrual of fat in the liver, besides pushing for more generation of VLDL, which tilts the plasma lipid balance towards a proatherogenic direction along with CVD-facilitating milieu.¹³² Nevertheless, certain NAFLD-correlated SNPs result in dysfunctional VLDL liberation (TM6F2 as well as PNPLA3,¹³³ as well as microsomal triacylglycerol transfer protein (MTTP), along with phosphatidylethanolamine methyltransferase (PEMT)), hence resulting in a reduction of plasma lipids, with hence the provision of protection conferred to the heart. The genetic variant of PNPLA3, an enzyme encoding I148M (rs738409 C/G) and involved in the hydrolysis of triacylglycerols in adipocytes, has been reported to be associated with NAFLD independent of the metabolic syndrome. Similarly, the genetic variant of the lipid transporter located on the ER (endoplasmic reticulum) and ER-Golgi compartments, TM6SF2 (transmembrane 6 superfamily member 2), encoding E167K (rs58542926 C/T), causes loss of function of the protein and increases hepatic deposition of triglycerides.¹³⁴ What are the ways by which genetic differences disrupt the generation (expression, formation) of these organokines, hence the proneness to generating metabolic diseases of the liver along with different organs? Recently, we had already emphasized the role of ER stress in T2DM, so no further details

were provided.¹³⁵

Diet as well as Gut Microbiota

The metabolism of certain dietary substances takes place by GM, generating metabolites that have the capacity to modulate the host metabolism. Conversely, diet possesses the capacity to manipulate microbiota diversity and, sequentially, advantageous or inimical actions in the host. These diet disruptions might be restricted to the gut; however, others possess systemic actions resulting in IR and might be associated with MetS risk factors.^{9,136} Moreover, diet controls certain organokines like FGF21.¹³⁶

Certain publications have illustrated the association between the microbiome and NAFLD and NASH pathogenesis, apart from the fact that crosstalk between gut and liver (the gut-liver axis) plays a key role in the generation of NASH besides its evolution.¹³⁷ Microbiome-obtained constituents can impact the liver through biomarkers leading to actions that are mutually connected, like gene expression, pro-inflammatory signaling, and manipulations in metabolism leading to toxicity leading to liver inflammation and fibrosis.¹³⁸

Different assumptions are feasible: a diet disrupts the microbiota, which disrupts the generation of metabolites correlated with MetS (directly correlated with NAFLD or NASH). At the time of liver inflammation, the liberation of organokines (hepatokines) changed; probably crosstalk amongst other organokines changed, an aggravating event in a vicious cycle. Hence the query arises: is it feasible that GM modulates the formation of organokines? What is the way GM disrupts the expression of hepatokines in patients with liver disease? In the case of the gut-liver axis, which plays a part in the pathogenesis and propagation of NASH, the maximum probability is that alterations in GM impact NASH generation and indirectly *via* hepatokines liberation. Since hepatokines take part in the metabolism of other organs and tissues like the pancreas, AT, and muscle, they might be impacted.

Exercise

Certain scientists believe that exercise and the maintenance of muscle mass might modulate circulating quantities of different organokines. Liver steatosis and fibrosis in patients with NAFLD might be avoided independently of weight reduction. The advantages of exercise are apparently correlated with the modulation of crosstalk amongst organs, leading to organokine balance, reduced inflammation, and OS.¹³⁹

Sleep, Melatonin Relation with Organokines

It is acknowledged that a correlation exists between physical activity and melatonin liberation, which in turn impacts the skeletal muscle makeup (fiber types) and its metabolism. As skeletal muscle liberates myokines and crosstalks with other organs, it is believed that a probable causative association exists between melatonin generation, organokine liberation, and the extent of inflammation. This might be associated with the generation of NAFLD and NASH.

Sleep deprivation and bad sleep quality are considerably responsible for the pathogenesis of metabolic impairment, including NAFLD.¹⁴⁰ If NAFLD/NASH is existent, it is feasible that changes in hepatokines liberation will take place. Sequentially, it might change the liberation of other organokines and crosstalk.

Certain publications have assessed the association between melatonin and skeletal muscle metabolism.¹⁴¹ Muscle is acknowledged to liberate myokines with variable metabolic actions. The query initiated is: is there a correlation between melatonin and myokine liberation? If so, can endogenous formation or therapeutic melatonin disturb the generation of organokines? Would it possess any therapeutic advantages? The mode by which sleep quality can disrupt quantitative and qualitative organokine liberation.

Other Metabolic Situations

It is feasible that other situations like iron overload (hyperferritinemia) or dysmetabolic iron overload syndrome can change the generation of these hepatokines, thus causing sequential crosstalks. Does this play a part in the pathogenesis and propagation of NASH (circuit and feedback)?

Management and Treatment


For the NASH generation, the two-hit model is acknowledged. Numerous organokines take part in the 1st or 2nd hit, hence impacting the liver disease initiation. Apart from that, since organokines might be implicated in initiating NAFLD, followed by propagation to NASH, it is plausible to utilize a dose of these biomarkers as a marker of liver disease and propagation.

In the future, we can consider whether there is a probability of pharmacological manipulation of organokine generation. Can we use it as a therapeutic approach for regulating T2D, obesity, MetS, hypertension, CVD and NASH?

CONCLUSION AND FUTURE DIRECTIONS

With the obesity pandemic and subsequently escalated NAFLD cases, the incidence of HCC is not only increasing with NAFLD progressing to cirrhosis but in earlier stages as well. Hence the significance of earlier diagnosis and the avoidance of NAFLD generation. Hence, the group of Yang et al¹⁴² has generated regulatory networks and crosstalk among various organokines. Yang et al¹⁴² further detailed the stellakines generated by HSCs. Moreover, they have developed an ingenuity pathway analysis (IPA) regarding variable organokines. Furthermore, they have found an association between NF κ B signaling and variable organokines (Figure 8). On that basis, they have evaluated the role of silymarin in NAFLD and NASH.

Activated HSCs secrete numerous pro-inflammatory factors and generate ECM components like α -SMA, type I and type III collagen fibers, which guide liver inflammation and modulate hepatocyte demise, hence facilitating the generation of liver disease.



The four main flavonolignan isomers in silymarin are silybin, isosilybin, silymarin, and silybin. Silymarin has antioxidant properties, anti-inflammatory properties, anti-fibrotic actions, and IR manipulation.

Its mode of action, silymarin, escalates the generation of glutathione in the liver by escalating the accessibility of cysteine, its biosynthetic substrate, which in turn aids in escalating its antioxidant ability in liver tissue. The main modes of action of silymarin in protecting liver cells are: (1) stabilization of membrane permeability by hampering lipid peroxidation and aiding the liver in the sustenance of quantities of glutathione; (2) silymarin also blocks the activation of NF- κ B by hampering the formation of TNF- α , interferon- γ , IL-2, and IL-4, thus avoiding various actions of toxic chemicals like carbon (3) It further hampers the expression of TNF-stimulated by α -amanita toxin of the poisonous mushroom, etc.¹⁴³

Of the various trials of silymarin conducted in Malaysia, the USA, and Pakistan, finally, Phase III clinical trials have validated that silymarin is the most beneficial drug for NAFLD patients currently; however, its standardization, dosage form, and dosage regimen are tough problems to overcome now. Together, these outcomes point out that silymarin treatment is efficacious in decreasing fibrosis, liver stiffness, and metabolic markers (alanine transaminase (ALT) and aspartate transaminase ((AST)); improving OS and endothelial impairment; and postponing disease propagation invariable areas. Silymarin is anticipated to be an efficacious therapeutic drug for NAFLD and NASH (Figure 8).¹⁴⁴ Hence, greater research on these organokines regarding NAFLD and NASH would be followed by more therapeutic targets by targeting any of these organokines to be able to avoid deaths in

young subjects even in early NAFLD from HCC.

CONFLICTS OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES

- Gariani K, Jornayvaz FR. Pathophysiology of NASH in endocrine diseases. *Endocr Connect.* 2021; 10: R52-R65. doi: 10.1530/EC-20-0490
- Ayada I, Van Kleef LA, Alferink LJM, Li P, De Knight RJ, Pan Q. Systematically epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: Focusing on the nonoverlap groups. *Liver Int.* 2021; 42: 277-287. doi: 10.1111/liv.15139
- Tilg H, Effenberger M. From NAFLD to MAFLD: When pathophysiology succeeds. *Nat Rev Gastroenterol Hepatol.* 2020; 17: 387-388. doi: 10.1038/s41575-020-0316-6
- Eslam M, Sanyal AJ, George J, Sanyal A; International Consensus Panel. MAFLD: A Consensus driven proposed nomenclature for metabolic fatty liver disease. *Gastroenterology.* 2020; 158: 1999-2014.e1. doi: 10.1053/j.gastro.2019.11.312
- Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction – associated fatty liver disease. *J Hepatol.* 2020; 73: 202-209. doi: 10.1016/j.jhep.2020.03.039
- De A, Ahmad N, Mehta M, Singh P, Duseja A. NAFLD vs MAFLD – it is not the name but the disease that decides the out-

- come of fatty liver. *J Hepatol.* 2021; 76: 475-477. doi: [10.1016/j.jhep.2021.09.002](https://doi.org/10.1016/j.jhep.2021.09.002)
7. Day CP, James OF. Steatohepatitis: A tale of two hits? *Gastroenterology.* 1998; 114: 842-845. doi: [10.1016/s0016-5085\(98\)70599-2](https://doi.org/10.1016/s0016-5085(98)70599-2)
8. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: Current concepts and future challenges. *Nat Rev Gastroenterol Hepatol.* 2019; 16: 411-28. doi: [10.1038/s41575-019-0145-7](https://doi.org/10.1038/s41575-019-0145-7)
9. Jiang X, Zheng J, Zhang S, Wang B, Wu C, Guo X. Advances in the involvement of gut microbiota in pathophysiology of NAFLD. *Front Med.* 2020; 7: 361. doi: [10.3389/fmed.2020.00361](https://doi.org/10.3389/fmed.2020.00361)
10. Lonardi A, Mantovani A, Lugari S, Targher S. Epidemiology and pathophysiology of the association between metabolically healthy or metabolically unhealthy Obesity. *Ann Hepatol.* 2020; 19: 359-366. doi: [10.1016/j.aohp.2020.03.001](https://doi.org/10.1016/j.aohp.2020.03.001)
11. Margiotti dos Santos JF, DeMailoMC, Lemes MA, et al. Non-alcoholic steatohepatitis (NASH) and organokines: What is now and what will be in the future. *Int J Mol Sci.* 2022; 23: 498. doi: [10.3390/ijms23010498](https://doi.org/10.3390/ijms23010498)
12. Sheka AC, Adeyi O, Thompson J, Hameed B, Cawford PA, Ikramuddin S. Non-alcoholic steatohepatitis: A review. *JAMA.* 2020; 323: 1175-1183. doi: [10.1001/jama.2020.2298](https://doi.org/10.1001/jama.2020.2298)
13. DiStefano JK. NAFLD and NASH in post menopausal women: implications for diagnosis and treatment. *Endocrinology.* 2020; 161: bqaa134. doi: [10.1210/endo/bqaa134](https://doi.org/10.1210/endo/bqaa134)
14. Kim H, Lee DS, An TH, et al. Metabolic spectrum of Liver-failure in type 2 Diabetes and obesity: From NAFLD to NASH to HCC. *Int J Mol Sci.* 2021; 22: 4495. doi: [10.3390/ijms22094495](https://doi.org/10.3390/ijms22094495)
15. Kaur KK, Allahbadia GN. Therapeutic applications of the recent understanding of brown or beige adipocyte physiology. *Adv Tech Biol Med.* 2015; 3: 128. doi: [10.4172/2379-1764.1000128](https://doi.org/10.4172/2379-1764.1000128)
16. Kaur KK, Allahbadia GN, Singh M. Advances in BAT physiology for understanding and translating into pharmacotherapies for obesity and comorbidities. *MOJ Drug Des Develop Ther.* 2018; 2(5): 166-176. doi: [10.15406/mojddt.2018.02.00057](https://doi.org/10.15406/mojddt.2018.02.00057)
17. Kaur KK, Allahbadia GN, Singh M. Weight loss associated with high protein diet intake in obesity: Interactions of gut microbiota in protein sources influencing this positive effect. *Acta Scientific Nutritional Health.* 2018; 2(7): 80-89.
18. Kaur KK, Allahbadia GN, Singh M. A mini review on development of newer therapies for non-alcoholic fatty acid liver disease with emphasis on vitamin D and its receptor and allyl isothiocyanate (AITC). *Acta Scientific Nutritional Health.* 2019; 3(12): 1-5.
19. Kaur KK, Allahbadia GN, Singh M. An update on further progression of NAFLD, NASH with prospective therapies like L-Carnitine (LC), Nicotinamide Ribose (NR) combination, as well as apical sodium dependent bile acids transporter (ASBT) or volixibat and silybin as alternatives. *Int J Clin Med Cases.* 2020; 3(3): 138. doi: [10.31021/ijcmc.20203138-29/1/2020](https://doi.org/10.31021/ijcmc.20203138-29/1/2020)
20. Kaur KK, Allahbadia GN, Singh M. Have probiotics and synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review. *Adv Obes Weight Manag Control.* 2019; 9(1): 21-28. doi: [10.15406/aowmc.2019.09.00269](https://doi.org/10.15406/aowmc.2019.09.00269)
21. Kaur KK, Allahbadia GN, Singh M. Will probiotics provide the answer for therapy of non-alcoholic fatty liver disease (NAFLD)? – a systematic review. *Biochem Physiol.* 2020; 9: 257.
22. Kaur KK, Allahbadia GN, Singh M. Are we any close to unraveling the mechanism of interactions among susceptibility genes towards type 1 diabetes, gut microbiota along with environmental factors, specifically early diet patterns – a systematic review. *J Endocrinology and Surgical Endocrinology.* 2021; 2(1): 1-20.
23. Kaur KK, Allahbadia GN, Singh M. How do we apply advances in knowledge of hepatic macrophages in treating liver diseases especially non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), with the increasing incidence of diabetes-a systematic review. *EC Endocrinology and Metabolic Research.* 2021.
24. Kaur KK, Allahbadia GN, Singh M. Mechanisms that associate extension of Nonalcoholic fatty liver diseases (NAFLD) to NASH (Non-alcoholic steatohepatitis) and further progressing to cirrhosis and Hepatocellular carcinoma (HCC) in addition to few proposed biomarkers for poor prognosis. *J Gynaecol.* 2021; 1(16): 1-18.
25. Kaur KK, Allahbadia GN, Singh M. How can we optimize therapy of non-alcoholic fatty acid liver disease-a short communication on role of astragaloside IV and other prospective agents. *Clinical Research and Clinical Case Reports.* 2021; 1(3): 1-4.
26. Kaur KK, Allahbadia GN, Singh M. Intestinal immune system in the regulation of obesity and metabolic syndrome-therapeutic implications-a systematic review. *EC Clinical and Experimental Anatomy.* 2020; 3(7): 7-22.
27. Kaur KK, Allahbadia GN, Singh M. An update on management of non-alcoholic fatty liver disease & nonalcoholic steatohepatitis-is the time ripe for achieving resolution of NAFLD & NASH soon. *J Endocrinol Res.* 2021; 3(2): 44-60. doi: [10.30564/jer.v3i2.3580](https://doi.org/10.30564/jer.v3i2.3580)
28. Kaur KK, Allahbadia GN, Singh M. The Association of non viral liver diseases from NAFLD to NASH to HCC with the pandemic of obesity, type 2 diabetes, or diabetes & metabolic syndrome – etiopathogenetic correlation along with utilization for diagnostic & therapeutic purposes-a systematic review. *J Endocrinol Res.* 2021; 3(2): 10-34. doi: [10.30564/jer.v3i2.3520](https://doi.org/10.30564/jer.v3i2.3520)

29. Kaur KK. Advantages and limitations of utilizing clostridium species as probiotics-a systematic review. Paper presented at: In a webinar held by Gastroenterology Conference; September 30, 2020. Punjab, India. <https://www.longdom.org/open-access-pdfs/advantages-and-limitations-of-utilizing-clostridium-species-as-probiotics-systematic-review.pdf>. Accessed December 15, 2022.
30. Kaur KK, Allahbadia GN, Singh M. The association of dietary fatty acids and gut microbiota alterations in the development of neuropsychiatric diseases: A systematic review. *Obes Res Open J.* 2020; 7(1): 19-45. doi: [10.17140/OROJ-7-143](https://doi.org/10.17140/OROJ-7-143)
31. Kaur KK, Allahbadia GN, Singh M. Role of adipocyte impairment in heart failure induction in subjects that are obese along with prediabetes and overt diabetes mellitus - a systematic review. *Int J Cardiol & Card.* 2021; 2(2): 1-21.
32. Kaur KK, Allahbadia GN, Singh M. An update on the association of gut-liver axis with gut microbiome dysbiosis correlated NAFLD along with NAFLD- HCC with potential therapeutic approaches: A systematic review. *J Hepatol Gastroenterol.* 2022; 8: 216. doi: [10.35248/2475-3181.22.8.216](https://doi.org/10.35248/2475-3181.22.8.216)
33. Armandi A, Rosso C, Caviglia GP, Bglanesi E. Insulin resistance across the spectrum of non-alcoholic fatty liver disease. *Metabolites.* 2021; 11: 155. doi: [10.3390/metabo11030155](https://doi.org/10.3390/metabo11030155)
34. Attia SL, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD/NASH. *Clin Transl Sci.* 2021; 14: 11-19. doi: [10.1111/cts.12839](https://doi.org/10.1111/cts.12839)
35. Xiao X, Hu Q, Deng X, et al. Old wine in new bottles: Kaempferol is a promising agent for treating triology of liver diseases. *Pharmacol Res.* 2021; 175: 106005. doi: [10.1016/j.phrs.2021.106005](https://doi.org/10.1016/j.phrs.2021.106005)
36. Longo M, Paolini M, Meroni M, Dongiovanni P. Remodeling of mitochondrial plasticity: The key switch from NAFLD to NASH to HCC. *Int J Mol Sci.* 2021; 22: 4173. doi: [10.3390/ijms22084173](https://doi.org/10.3390/ijms22084173)
37. Pierantonelli I, Svegliati-Baroni G. Non-alcoholic fatty liver disease: Basic pathogenetic mechanism in the progression from NAFLD to NASH. *Transplantation.* 2019; 103: e1-e13. doi: [10.1097/TP.0000000000002480](https://doi.org/10.1097/TP.0000000000002480)
38. Softic S, Meyer JG, Wang GX, et al. Dietary sugars after hepatic fatty acids oxidation via transcriptional and posttranscriptional modifications of mitochondrial proteins. *Cell Metab.* 2019; 30: 735-754.e4. doi: [10.1016/j.cmet.2019.09.003](https://doi.org/10.1016/j.cmet.2019.09.003)
39. Dong J, Viswanathan S, Adami E, et al. Hepatocyte specific IL11 signaling drives lipotoxicity and underlies the transition from NAFLD to NASH. *Nat Commun.* 2021; 12: 66. doi: [10.1038/s41467-020-20303-z](https://doi.org/10.1038/s41467-020-20303-z)
40. Jensen T, Abdelmalek MF, Sullivan S, et al. Fructose and sugar: A major mediator of non-alcoholic steatohepatitis. *J Hepatol.* 2018; 68(5): 1063-1075. doi: [10.1016/j.jhep.2018.01.019](https://doi.org/10.1016/j.jhep.2018.01.019)
41. Jegatheesan P, De Bandt JP. Fructose and NAFLD: The multifaceted aspects of fructose metabolism. *Nutrients.* 2017; 9: 230. doi: [10.3390/nu9030230](https://doi.org/10.3390/nu9030230)
42. DiStefano JK. Fructose mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis. *Cell Mol Life Sci.* 2020; 77(11): 2079-2090. doi: [10.1007/s00018-019-03390-0](https://doi.org/10.1007/s00018-019-03390-0)
43. Muriel P, Lopez- Sanchez P, Ramos-Tovar E. Fructose and the liver. *Int J Mol Sci.* 2021; 22: 6969. doi: [10.3390/ijms22136969](https://doi.org/10.3390/ijms22136969)
44. Chan AML, Ng AMH, Yunus MHM, et al. Recent development in rodent models of high fructose diet-induced metabolic syndrome: A systematic review. *Nutrients.* 2021; 13: 2497. doi: [10.3390/nu13082497](https://doi.org/10.3390/nu13082497)
45. Eshraghian A, Nikeghbalian S, Geramizadeh B, Kazemi K, Shamsaefar A, Malek-Hosseini SA. Characterization of biopsy proven non-alcoholic fatty liver disease in healthy non obese and lean population of living liver donors: The impact of uric acid. *Clin Res Hepatol Gastroenterol.* 2020; 44: 572-578. doi: [10.1016/j.clinre.2019.09.002](https://doi.org/10.1016/j.clinre.2019.09.002)
46. Cui Y, Liu J, Shi H, Hu W, Song L, Zhao O. Serum uric acid is positively associated with the prevalence of Non-alcoholic fatty liver in non obese type 2 Diabetic patients in Chinese populations. *J Diabetes Complications.* 2021; 35: 107874. doi: [10.1016/j.jdiacomp.2021.107874](https://doi.org/10.1016/j.jdiacomp.2021.107874)
47. Frederico A, Rosato V, Masarone M, et al. The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights. *Nutrients.* 2021; 13: 1314. doi: [10.3390/nu13041314](https://doi.org/10.3390/nu13041314)
48. Perez-Montes de Oca A, Julian MT, Ramos A, Puig Domingo M, Alonso N. Microbiota, fiber and NASH: Is there any connection? *Nutrients.* 2020; 12: 3100. doi: [10.3390/nu12103100](https://doi.org/10.3390/nu12103100)
49. Vasques-Monteiro IML, Silva-Veiga FM, Miranda CS, de Andrade Gonçalves ECB, Daleprane JB, Souza-Mello V. A rise in Proteobacteria is an indicator of gut-liver axis mediated non-alcoholic fatty liver disease in high-fructose-fed adult mice. *Nutr Res.* 2021; 91: 26-35. doi: [10.1016/j.nutres.2021.04.008](https://doi.org/10.1016/j.nutres.2021.04.008)
50. Semmler G, Datz C, Reiberger T, Trauner M. Diet and exercise in NAFLD/NASH: Beyond the obvious. *Liver Int.* 2021; 41: 2249-2268. doi: [10.1111/liv.15024](https://doi.org/10.1111/liv.15024)
51. Marusic M, Palc M, Knobloch M, Liberati Praso A-M. NAFLD, insulin resistance and diabetes mellitus type 2. *Can J Gastroenterol Hepatol.* 2021; 2021: 6613827. doi: [10.1155/2021/6613827](https://doi.org/10.1155/2021/6613827)
52. Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, et al. Novel antisense inhibition of Diacylglycerol- acetyl transferase for treatment of non-alcoholic fatty liver disease: A multicenter, double blinded, randomized placebo-controlled parallel,

- phase 2 Clinical trial. *Lancet Gastroenterol Hepatol.* 2020; 5: 829-38. doi: [10.1016/S2468-1253\(20\)30186-2](https://doi.org/10.1016/S2468-1253(20)30186-2)
53. Kirk B, Feehan J, Lombardi G, Duque G. Muscle, bone and fatcrosstalk: The biological role of myokines, osteokines and adipokines. *Curr Osteoporosis Res.* 2020; 18: 388-400. doi: [10.1007/s11914-020-00599-y](https://doi.org/10.1007/s11914-020-00599-y)
54. Kukukoglu O, Sowa JP, Mazzolini GD, Syn WK, Canbay A. Hepatokines and adipokines myokines in NASH related Hepatocellular carcinoma. *J Hepatol.* 2021; 74: 442-57. doi: [10.1016/j.jhep.2020.10.030](https://doi.org/10.1016/j.jhep.2020.10.030)
55. Choi KM. The impact of organokineson insulin resistance, inflammation and atherosclerosis. *Endocrinol Metab.* 2016; 31: 1-6. doi: [10.3803/EnM.2016.31.1.1](https://doi.org/10.3803/EnM.2016.31.1.1)
56. Petta S, Gestaldelli A, Rebelos A, et al. Pathophysiology of non-alcoholic fatty liver disease: Multiple interactions. *Int J Mol Sci.* 2016; 17: 2082. doi: [10.3390/ijms17122082](https://doi.org/10.3390/ijms17122082)
57. De Oliveira Mar Santodos Santos AR, De Oliveira Zanuso B, Miola VFB, et al. Adipokines, myokines and hepatokines: Crosstalk and repercussions. *Int J Mol Sci.* 2021; 22: 2639. doi: [10.3390/ijms22052639](https://doi.org/10.3390/ijms22052639)
58. Panera N, Corte CD, Crudele A, Stronati L, Nobili V, Alisi A. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. *Expert Rev Gastroenterol Hepatol.* 2016; 10: 393-403. doi: [10.1586/17474124.2016.1110485](https://doi.org/10.1586/17474124.2016.1110485)
59. Marques V, Afonso MB, Bierig N, et al. Adiponectin, leptin and IGF1are useful diagnostic and stratification biomarkers of NAFLD. *Front Med (Lausanne).* 2021; 8: 683250. doi: [10.3389/fmed.2021.683250](https://doi.org/10.3389/fmed.2021.683250)
60. Polyzos SA, Kountouras J, Anastasilakis AD. Irisin in non-alcoholic fatty liver disease: Need for updated meta-analysis. *Metabolism.* 2021; 121: 154818. doi: [10.1016/j.metabol.2021.154818](https://doi.org/10.1016/j.metabol.2021.154818)
61. Zorena K, Jachimowicz-Duda O, Slezak D, Rabakowska M, Mrugacz M. Adipokines and obesity: Potential link to metabolic disorders and chronic complications. *Int J Mol Sci.* 2020; 21: 3570. doi: [10.3390/ijms21103570](https://doi.org/10.3390/ijms21103570)
62. Han D, Chen L, Liu S, et al. Serum resistin levelsin adult patientswith non-alcoholic fatty liver disease: A systematic review and meta-analysis. *J Clin Transl Hepatol.* 2021; 9: 484-493. doi: [10.14218/JCTH.2021.00018](https://doi.org/10.14218/JCTH.2021.00018)
63. Deb A, Deshmukh B, Ramteke P, Bhati FK, Bhat MK. Resistin: A journey from metabolism to cancer. *Transl Oncol.* 2021; 14: 101178. doi: [10.1016/j.tranon.2021.101178](https://doi.org/10.1016/j.tranon.2021.101178)
64. Polyzos SA, Kountouras J, Anastasilakis AD, Geldari EV, Mantzoros CS. Irisin in patients with non-alcoholic fatty liver disease. *Metabolism.* 2014; 63: 207-217. doi: [10.1016/j.metabol.2013.09.013](https://doi.org/10.1016/j.metabol.2013.09.013)
65. Ke Y, Xu C, Lin J, Li Y. Role of hepatokines in non-alcoholic fatty liver disease. *J Transl Int Med.* 2019; 7: 143-148. doi: [10.2478/jtim-2019-0029](https://doi.org/10.2478/jtim-2019-0029)
66. Diaz BB, Gonzalez DA, Gannar F, Perez MCR, De Leon AC. Myokines, physical activity, insulin resistance and autoimmune diseases. *Immunol Lett.* 2018; 203: 1-5. doi: [10.1016/j.imlet.2018.09.002](https://doi.org/10.1016/j.imlet.2018.09.002)
67. Gonzalez-Gil AM, Elizando-Mmontemayor L. The role of exercise in the interplay between myokines, hepatokines, osteokines and adipokines and modulation of inflammation for energy substrate redistribution and fat mass loss. *Nutrients.* 2020; 12: 1899. doi: [10.3390/nu12061899](https://doi.org/10.3390/nu12061899)
68. Lebensztejn DM, Flisiak-Jackiwicz M, Bialokoz-Kalinowska J, Bobrus-Chociej A, Kowalska I. Hepatokines and non-alcoholic fatty liver disease. *Acta Biochem Pol.* 2016; 63: 459-67. doi: [10.18388/abp.2016_1252](https://doi.org/10.18388/abp.2016_1252)
69. Berja-Fernandez S, Folguiera C, Castelao C, et al. ANGPTL-4 is associated with obesity and lipid profile in children and adolescents. *Nutrients.* 2019; 11: 1340. doi: [10.3390/nu11061340](https://doi.org/10.3390/nu11061340)
70. Takata N, Ishii K, Takayama H, et al. LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophagesin NASH. *Sci Rep.* 2021; 11: 555. doi: [10.1038/s41598-020-80689-0](https://doi.org/10.1038/s41598-020-80689-0)
71. Saez-Lopez C, SalcedoAllendeMT, Hernandez C, Simo Servat O, Simo R, Selva DM. Sex hormone binding globulin expression correlates with acetyl-coenzyme A carboxylase and triglyceride content in the liver. *J Clin Endocrinol Metab.* 2019; 104: 1500-1507. doi: [10.1210/jc.2018-00740](https://doi.org/10.1210/jc.2018-00740)
72. Chen M-J, Ho H-N. Hepatic manifestations of women with polycystic ovary syndrome. *Best Pract Res Clin Obstet Gynaecol.* 2016; 37: 119-128. doi: [10.1016/j.bpobgyn.2016.03.003](https://doi.org/10.1016/j.bpobgyn.2016.03.003)
73. Fasshauer M, Bluher M. Adipokines in health and disease. *Trends Pharm Sci.* 2015; 36: 461-470. doi: [10.1016/j.tips.2015.04.014](https://doi.org/10.1016/j.tips.2015.04.014)
74. Baboota RK, Bluher M, Smith U. Emerging role of bone morphogenetic protein-4 in metabolic disorders. *Diabetes.* 2021; 70: 303-312. doi: [10.2337/db20-0884](https://doi.org/10.2337/db20-0884)
75. Colaianni G, Storlino G, Sanesi L, Colucci S, Grano M. Myokines and osteokines in the pathogenesis of muscle and bone diseases. *Curr Osteoporosis Rep.* 2020; 18: 401-407. doi: [10.1007/s11914-020-00600-8](https://doi.org/10.1007/s11914-020-00600-8)
76. Cobbina E, Akhlagi E. Non-alcoholic fatty liver disease (NAFLD)-pathogenesis, classification and effects on metabolizing enzymes and transporters. *Drug Metab Rev.* 2017; 49: 197-211. doi: [10.1080/03602532.2017.1293683](https://doi.org/10.1080/03602532.2017.1293683)

77. Ezquerro S, Mocha F, Fruhbeck G, et al. Ghrelin reduces human hepatocytes apoptosis, autophagy, and pyroptosis: Role in obesity associated NAFLD. *J Clin Endocrinol Metab.* 2019; 104: 21-37. doi: [10.1210/jc.2018-01171](https://doi.org/10.1210/jc.2018-01171)
78. Yang L, Roh YS, Song J, et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. *Hepatology.* 2014; 59: 483-95. doi: [10.1002/hep.26698](https://doi.org/10.1002/hep.26698)
79. Barbalho SM, Flato UAP, Tofar RJ, et al. Physical exercise and myokines: Relationship with sarcopenia and cardiovascular complications. *Int J Mol Sci.* 2020; 21: 3607. doi: [10.3390/ijms21103607](https://doi.org/10.3390/ijms21103607)
80. Xie C, Chen Q. Adipokines: New therapeutic targets for Osteoarthritis. *Curr Rheumatol Rep.* 2019; 21: 71. doi: [10.1007/s11926-019-0868-z](https://doi.org/10.1007/s11926-019-0868-z)
81. An X, Liu J, Li Y, et al. Chemerin/CMKLR1 ameliorated non-alcoholic steatohepatitis by promoting autophagy and alleviating oxidative stress through JAK2/STAT 3 pathway. *Peptides.* 2021; 135: 170422. doi: [10.1016/j.peptides.2020.170422](https://doi.org/10.1016/j.peptides.2020.170422)
82. Ye D, Yang K, Zang S, et al. Lipocalin 2 mediates non-alcoholic steatohepatitis by promoting neutrophils macrophages crosstalk via the induction of CXCR2. *J Hepatol.* 2016; 65: 988-997. doi: [10.1016/j.jhep.2016.05.041](https://doi.org/10.1016/j.jhep.2016.05.041)
83. Moschen AR, Adolph TE, Gerner RR, Weiser V, Tilg H. Lipocalin 2: A master mediator of intestinal and metabolic inflammation. *Trends Endocrinol Metab.* 2017; 28: 388-397. doi: [10.1016/j.tem.2017.01.003](https://doi.org/10.1016/j.tem.2017.01.003)
84. Mazzolini G, Atorrasagasti C, Onorato A, et al. SPARC expression is associated with hepatic injury in rodents and humans with non-alcoholic fatty liver disease. *Sci Rep.* 2018; 8: 725. doi: [10.1038/s41598-017-18981-9](https://doi.org/10.1038/s41598-017-18981-9)
85. Onorato AM, Fiore E, Bayo J, et al. SPARC inhibition accelerates NAFLD-associated hepatocellular carcinoma development by dysregulating hepatic lipid metabolism. *Liver Int.* 2021; 41: 1677-1643. doi: [10.1111/liv.14857](https://doi.org/10.1111/liv.14857)
86. Flisiak Jackiwicz M, Bobrus Chociej A, Wasilewska N, Tarasow E, Wotjowska M, Lebensztejn DM. Can hepatokines be regarded as non invasive serum biomarkers of intra hepatic lipid content in obese children? *Adv Med Sci.* 2019; 64: 280-284. doi: [10.1016/j.advms.2019.02.005](https://doi.org/10.1016/j.advms.2019.02.005)
87. Shojaie L, Iorga A, Dara L. Cell death in liver diseases: A review. *Int J Mol Sci.* 2020; 21(24): 9682. doi: [10.3390/ijms21249682](https://doi.org/10.3390/ijms21249682)
88. Xiong X, Kuang K, Ansari S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis. *Mol Cell.* 2019; 75(3): 644-660.e5. doi: [10.1016/j.molcel.2019.07.028](https://doi.org/10.1016/j.molcel.2019.07.028)
89. Chang E-J, Lee SK, Song YS, et al. IL-34 is associated with obesity, chronic inflammation, and insulin resistance. *J Clin Endocrinol Metab.* 2014; 99(7): E1268- E1271. doi: [10.1210/jc.2013-4409](https://doi.org/10.1210/jc.2013-4409)
90. Mohallem R, Aryal UK. Regulators of TNF: Mediated insulin resistance elucidated by quantitative proteomics. *Sci Rep.* 2020; 10(1): 20878. doi: [10.1038/s41598-020-77914-1](https://doi.org/10.1038/s41598-020-77914-1)
91. Sun S-C. The non-canonical NF- κ B pathway in immunity and inflammation. *Nat Rev Immunol.* 2017; 17(9): 545-58. doi: [10.1038/nri.2017.52](https://doi.org/10.1038/nri.2017.52)
92. Jin J, Hu H, Li HS, et al. Noncanonical NF- κ B pathway controls the production of type I interferons in antiviral innate immunity. *Immunity.* 2014; 40(3): 342-354. doi: [10.1038/nri.2017.52](https://doi.org/10.1038/nri.2017.52)
93. Konishi T, Schuster RM, Goetzman HS, Caldwell CC, Lentsch AB. Fibrotic liver has prompt recovery after ischemia-reperfusion injury. *Am J Physiol Gastroenterol Liver Physiol.* 2020; 318(3): G390-G400. doi: [10.1152/ajpgi.00137.2019](https://doi.org/10.1152/ajpgi.00137.2019)
94. Hong L, Shejiao D, Fenrong C, Gang Z, Lei D. Periostin down-regulation attenuates the pro-fibrogenic response of hepatic stellate cells induced by TGF- β . *J Cell Mol Med.* 2015; 19(10): 2462-2468. doi: [10.1111/jcmm.12636](https://doi.org/10.1111/jcmm.12636)
95. Prakoura N, Kavvadas P, Kormann R, Dussaule JC, Chadji-christos CE, Chatziantoniou C. NF- κ B-induced periostin activates integrin- β 3 signaling to promote renal injury in GN. *J Am Soc Nephrol.* 2017; 28(5): 1475-1490. doi: [10.1681/ASN.2016070709](https://doi.org/10.1681/ASN.2016070709)
96. Izuhara K, Nunomura S, Nanri Y, et al. Periostin in inflammation and allergy. *Cell Mol Life Sci.* 2017; 74(23): 4293-4303. doi: [10.1007/s00018-017-2648-0](https://doi.org/10.1007/s00018-017-2648-0)
97. Chen JY, He XX, Ma C, et al. Netrin-1 promotes glioma growth by activating NF- κ B via UNC5A. *Sci Rep.* 2017; 7(1): 5454. doi: [10.1038/s41598-017-05707-0](https://doi.org/10.1038/s41598-017-05707-0)
98. Deng Y, Li J, Zhou M, Liang Z, Zhao L. c-Myc affects hedgehog pathway via KCNQ1OT1/RAC1: A new mechanism for regulating HSC proliferation and epithelial-mesenchymal transition. *Dig Liver Dis.* 2021; 11(14): 1458-1467. doi: [10.1016/j.dld.2020.11.035](https://doi.org/10.1016/j.dld.2020.11.035)
99. Wang X, Liu Y, Zhang S, et al. Crosstalk between Akt and NF- κ B pathway mediates inhibitory effect of gas6 on monocytes-endothelial cells interactions stimulated by P. gingivalis-LPS. *J Cell Mol Med.* 2020; 24(14): 7979-7990. doi: [10.1111/jcmm.15430](https://doi.org/10.1111/jcmm.15430)
100. Peng CK, Wu CP, Lin JY, et al. Gas6/Axl signaling attenuates alveolar inflammation in ischemia-reperfusion induced acute lung injury by up-regulating SOCS3-mediated pathway. *PLoS One.* 2019; 14(7): e020219788. doi: [10.1371/journal.pone.0219788](https://doi.org/10.1371/journal.pone.0219788)
101. Yu B, Chang J, Liu Y, et al. Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor- κ B. *Nat Med.*

2014; 20(9): 1009-1017. doi: [10.1038/nm.3586](https://doi.org/10.1038/nm.3586)

102. Yin C, Ye Z, Wu J, et al. Elevated Wnt2 and Wnt4 activate NF- κ B signaling to promote cardiac fibrosis by cooperation of Fzd4/2 and LRP6 following myocardial infarction. *EBioMedicine*. 2021; 74: 103745. doi: [10.1016/j.ebiom.2021.103745](https://doi.org/10.1016/j.ebiom.2021.103745)

103. Mizukami J, Takaesu G, Akatsuka H, et al. Receptor activation of NF- κ B ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. *Mol Cell Biol*. 2002; 22(4): 992-1000. doi: [10.1128/MCB.22.4.992-1000.2002](https://doi.org/10.1128/MCB.22.4.992-1000.2002)

104. Korbecki J, Kojder K, Kapczuk P, et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature. *Int J Mol Sci*. 2021; 22(2): 843. doi: [10.3390/ijms22020843](https://doi.org/10.3390/ijms22020843)

105. Warner KA, Miyazawa M, Cordeiro MM, et al. Endothelial cells enhance tumor cell invasion through a crosstalk mediated by CXC chemokine signaling. *Neoplasia*. 2008; 10(2): 131-139. doi: [10.1593/neo.07815](https://doi.org/10.1593/neo.07815)

106. Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J Biol Chem*. 1995; 270(4): 27348-27357. doi: [10.1074/jbc.270.45.27348](https://doi.org/10.1074/jbc.270.45.27348)

107. Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF- κ B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. *Oncogene*. 2007; 26(52): 733-745. doi: [10.1038/sj.onc.1210536](https://doi.org/10.1038/sj.onc.1210536)

108. Sun Y, Xiong X, Wang X. RELA promotes hypoxia-induced angiogenesis in human umbilical vascular endothelial cells via LINC01693/miR-302d/CXCL12 axis. *J Cell Biochem*. 2019; 120(8): 12549-12558. doi: [10.1002/jcb.28521](https://doi.org/10.1002/jcb.28521)

109. Liu H, Li J, Tillman B, Morgan TR, French BA, French SW. TLR3/4 signaling is mediated via the NF- κ B-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies. *Exp Mol Pathol*. 2014; 97(2): 234-240. doi: [10.1016/j.yexmp.2014.07.001](https://doi.org/10.1016/j.yexmp.2014.07.001)

110. Liang K, Liu Y, Eer D, Liu J, Yang F, Hu K. High CXC chemokine ligand 16 (CXCL16) expression promotes proliferation and metastasis of lung cancer via regulating the NF- κ B pathway. *Med Sci Monitor*. 2018; 24: 405-411. doi: [10.12659/msm.906230](https://doi.org/10.12659/msm.906230)

111. Korbecki J, Kodjer K, Simińska D, et al. CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. *Int J Mol Sci*. 2020; 21(21): 8412. doi: [10.3390/ijms21218412](https://doi.org/10.3390/ijms21218412)

112. Miyagaki T, Sugaya M, Murakami T, et al. CCL11-CCR3 interactions promote survival of anaplastic large cell lymphoma cells via ERK1/2 activation. *Cancer Res*. 2011; 71(6): 2056-2065. doi: [10.1158/0008-5472.CAN-10-3764](https://doi.org/10.1158/0008-5472.CAN-10-3764)

113. Park JY, Kang YW, Choi BY, Yang YC, Cho BP, Cho WG. CCL11 promotes angiogenic activity by activating the PI3K/Akt pathway in HUVECs. *J Receptors Signal Transduction*. 2017; 37(4): 416-421. doi: [10.1080/10799893.2017.1298132](https://doi.org/10.1080/10799893.2017.1298132)

114. Jin L, Liu WR, Tian MX, et al. CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. *Oncotarget*. 2017; 8(3): 5135-5148. doi: [10.18632/oncotarget.14095](https://doi.org/10.18632/oncotarget.14095)

115. Waddell A, Ahrens R, Tsai YT, et al. Intestinal CCL11 and eosinophilic inflammation is regulated by myeloid cell-specific RelA/p65 in mice. *J Immunol*. 2013; 190(9): 604773-604785.

116. Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J. The NF- κ B p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. *J Hepatol*. 2010; 53(3): 519-527. doi: [10.1016/j.jhep.2010.03.025](https://doi.org/10.1016/j.jhep.2010.03.025)

117. Makino Y, Hikita H, Kodama T, et al. CTGF mediates tumor-stroma interactions between hepatoma cells and hepatic stellate cells to accelerate HCC progression. *Cancer Res*. 2018; 78(17): 4902-4914. doi: [10.1158/0008-5472.CAN-17-3844](https://doi.org/10.1158/0008-5472.CAN-17-3844)

118. Chaqour B, Yang R, Sha Q. Mechanical stretch modulates the promoter activity of the profibrotic factor CCN2 through increased actin polymerization and NF- κ B activation. *J Biol Chem*. 2006; 281(29): 20608-20622. doi: [10.1074/jbc.M600214200](https://doi.org/10.1074/jbc.M600214200)

119. Nagai N, Matoba K, Kawanami D, et al. ROCK2 regulates TGF- β -induced expression of CTGF and profibrotic genes via NF- κ B and cytoskeleton dynamics in mesangial cells. *Am J Physiol Renal Physiol*. 2019; 317(4): F839-F851. doi: [10.1152/ajprenal.00596.2018](https://doi.org/10.1152/ajprenal.00596.2018)

120. Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management. *World J Hepatol*. 2017; 9: 533-543. doi: [10.4254/wjv.v9.i11.533](https://doi.org/10.4254/wjv.v9.i11.533)

121. Jing YY, Han Z, Sun K, et al. Toll like receptor 4 signaling promotes epithelial-mesenchymal transition in human Hepatocellular carcinoma induced by lipopolysaccharides. *BMC Med*. 2012; 10: 98. doi: [10.1186/1741-7015-10-98](https://doi.org/10.1186/1741-7015-10-98)

122. Li H, Li Y, Liu D, Liu J. LPS promotes epithelial-mesenchymal transition and activation of TLR4/JNK signaling. *Tumor Biol*. 2014; 35: 10429-10435. doi: [10.1007/s13277-014-2347-5](https://doi.org/10.1007/s13277-014-2347-5)

123. Gupta H, Youn GS, Shin MJ, Suk KT. Gut microbiota in hepatocarcinogenesis. *Microorganisms*. 2019; 7: 121.

124. Saxena NK, Fu PP, Nagalingam A, et al. Adiponectin modulates c-jun N terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. *Gastroenterology*. 2010; 139: 1762-1773. doi: [10.1053/j.gastro.2010.07.001](https://doi.org/10.1053/j.gastro.2010.07.001)

125. Al-Gayyar AM, Abbas A, Hamdan AM. Chemopreventive and hepatoprotective role of Adiponectin (SULF2 Inhibitor) in hepatocellular carcinoma. *Biol Chem.* 2016; 397: 257-267. doi: [10.1515/hsz-2015-0265](https://doi.org/10.1515/hsz-2015-0265)
126. Kamada Y, Matsumoto H, Tamura S, et al. Hypo adiponectinemia accelerates hepatic tumorformation in non-alcoholic steatohepatitis mouse model. *J Hepatol.* 2007; 47: 556-564. doi: [10.1016/j.jhep.2007.03.020](https://doi.org/10.1016/j.jhep.2007.03.020)
127. Shen J, Yeh CC, Wang Q, et al. Plasma adiponectin and hepatocellular carcinoma survival among patients without liver transplantation. *Anticancer Res.* 2016; 36: 5307-5314. doi: [10.21873/anticancer.11103](https://doi.org/10.21873/anticancer.11103)
128. Stefanou N, Papanikolaou V, Furukawa Y, Nakamura Y, Tsezou A. Leptin as acritical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. *BMC Cancer.* 2010; 10: 442. doi: [10.1186/1471-2407-10-442](https://doi.org/10.1186/1471-2407-10-442)
129. Wei R, Hu Y, Dong F, Xu X, Hu A, Gao G. Hepatoma cell-derived leptin down regulates the immunosuppressive function of regulatory T cells to enhance the anti tumor activity of CD 8+T cells. *Immunol Cell Biol.* 2016; 94: 388-399. doi: [10.1038/icb.2015.110](https://doi.org/10.1038/icb.2015.110)
130. Sliz E, Sebert S, Wurtz P, et al. NAFLD risk alleles in PNPLA2, TM5SF2, GCKR and LYPLAL1 show divergent metabolic effects. *Hum Mol Genet.* 2018; 27: 2214-2223. doi: [10.1093/hmg/ddy124](https://doi.org/10.1093/hmg/ddy124)
131. Simons N, Isaacs A, Koek GH, Kuč S, Schaper NC, Brouwers MCGJ. PNPLA3, TM6F2 and MBOAT17 genotypes and coronary artery disease. *Gastroenterology.* 2019; 152: 912-9123. doi: [10.1053/j.gastro.2016.12.020](https://doi.org/10.1053/j.gastro.2016.12.020)
132. Kaur KK, Allahbadia GN, Singh M. An update on the risk factors correlating NAFLD with cardiovascular disease: Specifically mitochondrial - fatty acids β oxidation in liver with therapeutic approaches of avoidance of CVD associated mortality-A systematic review. *J Endocrinol.* 2022; 6(1): 1-20. doi: [10.23880/oaje-16000164](https://doi.org/10.23880/oaje-16000164)
133. Kaur KK, Allahbadia GN, Singh M. Synergistic anti oxidant actions of mitochondrial palatin-like phospholipaseA2 domain-containing protein-8 (PNPLA8/iPLA2 γ) with the fatty acids(FA)-translocating-SLC-25 gene family transporters with their sequelae-a review. *Int J Med B Health Res.* 2020; 4(1): 1-15.
134. Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. *Drug Metab Rev.* 2017; 49(2): 197-211. doi: [10.1080/03602532.2017.1293683](https://doi.org/10.1080/03602532.2017.1293683)
135. Kaur KK, Allahbadia GN, Singh M. An update on mechanistic modes in AGEs stimulated & ER and inflammatory stress-modulated control of the GLUT4 expression (SLC2A4 promoted) and atherogenesis in diabetes mellitus-a narrative review. *Mathews J Cytol Histol.* 2022; 6(1): 21. doi: [10.30654/MJCH.10021](https://doi.org/10.30654/MJCH.10021)
136. Zmora N, Suez J, Elinav E. You and what you eat: Diet, health and gut microbiota. *Nat Rev Gastroenterol Hepatol.* 2019; 16: 33-56. doi: [10.1038/s41575-018-0061-2](https://doi.org/10.1038/s41575-018-0061-2)
137. Janzi S, Gonzalez-Padilla E, Najafi K, et al. Single nucleotide polymorphisms in close proximity to the Fibroblast growth factor and 21 (FGF21) gene found to be associated with sugar intake in a Sweden population. *Nutrients.* 2021; 13: 3954. doi: [10.3390/nu13113954](https://doi.org/10.3390/nu13113954)
138. Safari Z, Gerard P. The links between the gut microbiome and Non-alcoholic fatty liver disease(NAFLD). *Cell Mol Life Sci.* 2019; 76: 1541-1558. doi: [10.1007/s00018-019-03011-w](https://doi.org/10.1007/s00018-019-03011-w)
139. Oh S, Tsujimoto T, Kim B, et al. Weight loss independent benefits of diet exercise on liver steatosis and stiffness in Japanese men with NAFLD. *JHEP Rep.* 2021; 3: 100253. doi: [10.1016/j.jhepr.2021.100253](https://doi.org/10.1016/j.jhepr.2021.100253)
140. Marjot T, Ray DW, Williams FR, Tomlinson JW, Armstrong MJ. Sleep and liver disease: A bidirectional relationship. *Lancet Gastroenterol Hepatol.* 2021; 6: 850-863. doi: [10.1016/S2468-1253\(21\)00169-2](https://doi.org/10.1016/S2468-1253(21)00169-2)
141. Staccchiotti A, Favero G, Rodella LF. Impact of melatonin on skeletal muscle and exercise. *Cells.* 2020; 9: 288. doi: [10.3390/cells9020288](https://doi.org/10.3390/cells9020288)
142. Yang B, Lu L, Zhou D, et al. Regulatory networks and interplay of hepatokines, stellakines, myokines adipokines, in non-alcoholic fatty liver diseases and non-alcoholic steatohepatitis. *Front Endocrinol (Lausanne).* 2022; 13: 1007944. doi: [10.3389/fendo.2022.1007944](https://doi.org/10.3389/fendo.2022.1007944)
143. Vaccher M, Bansal S, Kumar B, et al. Contribution of organokines in the development of NAFLD/NASH associated hepatocellular carcinoma. *J Cell Biochem.* 2022; 123(10): 1553-1584. doi: [10.1002/jcb.30252](https://doi.org/10.1002/jcb.30252)
144. Yang B, Yang X, Tan X, et al. Regulatory networks, management approaches and emerging treatments for non-alcoholic fatty liver diseases. *Can J Gastroenterol Hepatol.* 2022; 2022: 6799414. doi: [10.1155/2022/6799414](https://doi.org/10.1155/2022/6799414)